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ABSTRACT 
By 2004, t he existence of an endothelial-cell (EC) glycocalyx surface layer , rv 0.5 
f.-Lm in thickness, was well established in capillaries and venules in vivo. Recent re-
search has suggested many roles for t he glycocalyx in vascular physiology, while other 
studies have linked glycocalyx damage to mult iple vascular pathologies. In t his dis-
sertation , micro-particle image velocimetry and microviscometric analysis are applied 
in vivo to estimate the glycocalyx t hickness under normal physiological condit ions, 
in pathological st ates, and in genetic knock-out mice. 
Since t he glycocalyx is likely to have broad implications for EC function , it is 
necessary to determine t he extent to which it is present in arterioles . Results show 
the existence of a glycocalyx rv 0.4 f.-Lm t hick in arterioles, slight ly t hinner than t hat 
found in venules (p = 0.025). Data obtained t hroughout t he cardiac cycle indicate 
t hat glycocalyx t hickness does not fluctuate with flow variations arising from cardiac-
induced pulsatility. 
Heparan sulfate proteoglycans are t hought t o be major components of glycocalyx. 
To test whether syndecan-1 in particular is an essential glycocalyx anchoring protein, 
l V 
experiments were conducted in syndecan-1 deficient (Sdc1-/-) mice. Results indicate 
that the glycocalyx in Sdc1-/- mice is "'0.1 J-Lm thinner than in wild-type mice (p = 
0.03). Increased leukocyte adhesion was also observed in Sdc1-/ - mice. Therefore, 
while syndecan-1 is not a prerequisite for the existence of the glycocalyx, syndecan-1 
deficiency may alter glycocalyx composition and function. 
Hyperglycemia results in increased generation of reactive oxygen species, which 
have been shown to degrade glycocalyx. To assess the effects of hyperglycemia on the 
glycocalyx and the efficacy of treatments aimed at protecting the glycocalyx during 
hyperglycemia, experiments were performed in acutely and chronically hyperglycemic 
mice. Chronic hyperglycemia resulted in significant glycocalyx degradation. Treat-
ments aimed at reducing levels of oxidative stress significantly reduced, but did not 
eliminate, glycocalyx damage. 
While these investigations address many fundamental questions regarding the 
state of the glycocalyx under normal or pathological conditions, its structure, com-
position, and function still remain largely unknown. The presence of an intact glyco-
calyx may be critical to vascular health. FUture experiments are warranted to further 
explore the possible link between glycocalyx damage and vascular pathology. 
v 
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Chapter 1 
Introduction 
The Glycocalyx 
The endothelial-cell (EC) glycocalyx is a thin layer of macromolecules on the luminal 
surface of the vascular endothelium. It has been demonstrated to selectively exclude 
macromolecules and retard plasma flow within rv 0.5 j.J,m of the vessel wall in capil-
laries and venules in vivo [1-5]. While little is definitively known about its structure 
and composition, it has been suggested that the glycocalyx consists of a < 0.1 j.J,m 
thick layer of membrane-bound molecules at the EC surface and a rv 0.4- 0.5 j.J,m 
thick region of macromolecules adsorbed from the plasma at the blood- glycocalyx 
' interface [6-8] . The membrane-bound components, including glycoproteins , heparan 
sulfate proteoglycans (HSPGs), and glycosaminoglycans (GAGs), are considered to 
form the basic structure or 'backbone' of the glycocalyx, anchoring it to the EC 
surface. Under normal conditions, the ECs may actively regulate the glycocalyx 
composition in response to changes in their microenvironment by adjusting the rate 
of synthesis and secretion of the various components [7]. The adsorbed components, 
including plasma proteins and soluble GAGs, associate with this anionic structure 
through electrostatic interactions. This region of the glycocalyx is thought to be in 
dynamic equilibrium with flowing blood. This hypothetical structure, as described 
by Pries et al., is depicted in Fig. 1.1 [ 6]. 
Given its location at the interface between the vascular endothelium and flowing 
blood, the glycocalyx is situated to play a key role in many physiological functions . 
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Figure 1.1: Hypothetical structure of the endothelial glycocalyx, as described by Pries 
et al. [6]. In this proposed structure, the glycocalyx is anchored to the endothelium by 
membrane bound macromolecules. Adsorbed plasma proteins are thought to make up the 
bulk of the glycocalyx thickness and are presumed to be in dynamic equilibrium with flowing 
blood. (Reproduced from Pries et al., 2000 [6], with permission from the publisher.) 
There is evidence that it influences vascular permeability [2, 9, 10], is important for 
mechanotransduction [11], and modulates the inflammatory response by acting as a 
barrier to leukocyte adhesion [2, 12, 13]. The glycocalyx may represent the first line 
of defense for the endothelium against vascular damage. Damage to the glycocalyx 
has been implicated as part of several vascular pathologies, including atherosclerosis, 
ischemia/ reperfusion injury, and vascular disease resulting from diabetes [6, 8]. 
In this dissertation, micro-particle image velocimetry (,u-PIV) and microviscomet-
ric analysis are applied in vivo in mouse microvessels to estimate the hydrodynam-
ically relevant glycocalyx thickness under various experimental conditions. In order 
to gain further insight into the physiological significance and composition of the gly-
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cocalyx, experiments were performed in arterioles of wild-type (WT) mice and in 
venules of mice with genetically altered HSPG expression. To investigate the state of 
the glycocalyx, and its possible vasculoprotective role, in the pathology of diabetes, 
experiments were performed in venules of mice with acute and chronic hyperglycemia . 
Micro-particle Image Velocimetry and Microviscometric Analysis 
f.L-PIV and microviscometric analysis, developed by Damiano and coworkers, have 
been used to interrogate the glycocalyx in vivo [3-5] and in vitro [14, 15] . In the 
f.L-PIV method, dual-flash epi-illumination is used to capture the velocities and radial 
positions of fluorescent microspheres t raveling in the midsagittal plane of a microves-
sel [3, 5]. Microviscometric analysis is applied to the f.L-PIV data to estimate t he 
fluid velocity profile and "effective hydrodynamically relevant glycocalyx thickness", 
defined as t he thickness of the layer that significantly retards plasma flow. The viscos-
ity, shear rate, and shear stress distributions can then be estimated by applying the 
conservation of linear momentum. Microviscometric analysis of f.L-PIV data collected 
in venules ("' 20- 70 f.Lm in diameter) has revealed a "' 0. 5 f.Lm thick hydrodynamically 
relevant glycocalyx [4, 5, 14, 15]. Further details and discussion of these methods are 
given in Chapters 2 and 3. 
The Glycocalyx in Arterioles 
Several studies had assumed that a glycocalyx, similar to t hat found in capillaries 
and venules, also exists on arterioles [11, 16- 18]; however, that assumption had not 
been directly demonstrated in vivo. The differing hemodynamic environments be-
tween arterioles and venules may influence or even determine the extent to which 
the glycocalyx appears on arteriolar versus venular endothelium, which may in turn 
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have important implications for endothelial mechanotransduction, angiogenesis, and 
atherosclerosis. It is therefore necessary to determine the extent to which the glyco-
calyx is present on arteriolar endothelium in vivo. In Chapter 4, 11-PIV and micro-
viscometric analysis are modified for application to the unsteady fluid-flow regimes 
in arterioles. Due to the pulsatile nature of the flow in arterioles, data acquisition 
was triggered with the electrocardiogram (ECG) of the mouse at specific time points 
in the cardiac cycle. Results from data taken at peak systole in the cardiac cycle 
establish the existence of a hydrodynamically relevant glycocalyx that is rv 0.4 11m 
in thickness in arterioles. This is slightly thinner than the rv 0.5-f.Lm-thick glycocalyx 
found in venules. Results from data obtained at four equally spaced points through-
out the cardiac cycle indicate that the glycocalyx thickness in arterioles does not 
fluctuate with flow variations arising from cardiac-induced pulsatility. 
The Glycocalyx in Syndecan-1 Deficient Mice 
In Chapter 5, 11-PIV and microviscometric analysis are used to investigate the compo-
sition of glycocalyx. Of the molecules found at the EC surface, HSPGs are considered 
to be the key anchoring components for the glycocalyx. HSPGs found on the apical 
surface of ECs are syndecan-1, -2, and -4, and glypican-1 [19]. The extent to which 
any or all of these proteins might serve to anchor the glycocalyx to the endothelium 
has not previously been determined. To test whether syndecan-1, in particular, is 
an essential anchoring protein for the endothelial glycocalyx, experiments were per-
formed to estimate the glycocalyx thickness in syndecan-1 deficient (Sdcl-/-) mice. 
Results show that there is a hydrodynamically relevant glycocalyx in Sdcl-/- mice 
that is rv 0.1 11m thinner than that found in WT mice. Sdcl-/- mice also exhib-
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ited increased leukocyte adhesion relative to WT mice. It was concluded that, while 
syndecan-1 is not a prerequisite for the existence of the glycocalyx, syndecan-1 de-
ficiency may alter glycocalyx composition, which, in turn, may influence glycocalyx 
function, particularly under inflammatory challenge. 
The Effects of Hyperglycemia on the Glycocalyx 
Nearly all chronic complications of diabetes are derived from vascular disease arising 
from hyperglycemia, which has been linked to oxidative stress and EC dysfunction 
resulting from hyperglycemia-induced overproduction of superoxide by the mitochon-
drial electron transport chain [20, 21]. Previous experiments by Vink and Duling 
[1] have suggested that reactive oxygen species (ROS) degrade the glycocalyx, and 
that treatment with superoxide dismutasejcatalase (SOD/CAT) is protective of the 
glycocalyx. The objective of Chapter 6 is to establish the extent to which acute and 
chronic hyperglycemia degrade the glycocalyx, and whether this degradation can be 
prevented by treatments aimed at reducing levels of ROS and normalizing EC func-
tion during chronic hyperglycemia. Acute hyperglycemia ( < 4 hours) did not result 
in an immediate reduction in the hydrodynamically relevant glycocalyx thickness. 
Chronic hyperglycemia (approximately three weeks) in non-obese diabetic (NOD) 
mice resulted in degradation of the glycocalyx to rv 0.1~0.2 p,m in thickness. This 
is comparable to the level of glycocalyx degradation observed in the experiments of 
Vink and Duling [1]. Treatment with a synthetic SOD/CAT mimetic or the mito-
chondrial uncoupler 2,4 dinitrophenol (DNP) reduced, but did not completely prevent 
glycocalyx degradation in the presence of chronic hyperglycemia. 
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Chapter 2 
Background 
The concept of a non-cellular layer on the luminal surface of the vascular endothelium 
was first introduced by Danielli in 1940 and futher expanded on by Chambers and 
Zweifach in 1947 [22], who termed it the 'endocapillary layer'. While studying cap-
illary permeability in perfused frog legs, Danielli [23] observed that serum was more 
effective in reducing capillary permeability than other perfusates having a similar 
osmotic pressure. To explain this, he proposed the existence of a layer of adsorbed 
plasma proteins on the surface of the endothelium. This layer would be displaced by 
perfusates not containing blood components, resulting in an increase in permeability. 
It was also observed that when certain proteins were added to serum, capillary per-
meability increased. It was hypothesized that this increase was due to displacement 
of the adsorbed plasma proteins. Chambers and Zweifach [22] confirmed the perme-
ability findings of Danielli, and attempted, but were unable to visualize the layer in 
capillaries of the frog mesentery; however , they did observe a material sloughing off 
the endothelium when perfusing with Ringer 's solution containing Evans Blue, which 
binds to albumin. The removal of this material coincided with an increase in capillary 
permeability, which was reversed with the addition of serum to the perfusate. It was 
not until nearly two decades later that the first successful visualization of structures on 
the endothelial cell (EC) surface was accomplished by Luft with electron microscopy 
(EM) [24]. This revealed an irregular structure extending only rv 20 nm from the 
EC surface. It would be another 30 years before the full extent of the endothelial 
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glycocalyx was to be revealed in vivo, when Vink and Duling used their dye-exclusion 
method to demonstrate the existence of a rv 0.5-{Lm-thick layer in capillaries of the 
hamster cremaster muscle [1]. 
2.1 Electron Microscopy 
A wide variety of tissue fixation and staining methods have been used to visualize 
the endothelial glycocalyx with EM; however, the apparent thickness of the layer 
varied greatly depending on the particular method employed. While the first EM 
studies revealed a layer of only 100 nm or less, more recently developed methods 
show a layer up to 1 {Lm in thickness. In 1966, Luft used ruthenium red staining and 
glutaraldehyde/osmium tetraoxide fixation; the resulting images showed an irregular 
structure extending rv 20 nm into the capillary lumen. While this is only a small 
fraction of the rv 0.5-{Lm-thick layer later visualized in vivo, previous attempts to 
visualize the glycocalyx using either brightfield microscopy or EM without specific 
staining had been entirely unsuccessful [6]. 
Staining and fixation of tissue for EM can easily result in damage to the glycocalyx 
structure, by affecting electrostatic interactions, washing away plasma proteins, or 
dissolving the carbohydrate side-chains of glycoproteins and proteoglycans [6, 7, 25]. 
Sims and Horne [25] attempted to preserve the structure using fluorocarbon as a non-
aqueous fixative, but the resulting images still showed a glycocalyx with an average 
thickness less than 100 nm. Given the high water content of the glycocalyx, post-
fixation alcohol dehydration of the sample may also introduce artifacts [7]. 
More recently developed perfusion fixation protocols that do not include post-
fixation alcohol dehydration of the tissue are apparently able to preserve a larger 
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Figure 2.1: EM images of the endothelial glycocalyx obtained by Van den Berg et al. [10] 
using Alcian Blue staining show a"' 0.2-0.5-J.Lm-thick glycocalyx in capillaries (A). After 
treatment with hyaluronidase (B), the glycocalyx was< 0.1 J.Lm in thickness. (Reproduced 
from Van den Berg et al., 2003 [10], with permission from the publisher). 
portion of the glycocalyx, although the presence of other fixation artifacts, such as 
crystallization artifacts, cannot be entirely ruled out. In 2003, Van den Berg et al. 
reported a rv 0.2-0.5-JLm-thick glycocalyx in segments of capillaries from rat hearts 
that had been perfused in situ with a phosphate-buffered fixative containing Alcian 
Blue [10]. After treatment with hyaluronidase, the layer was degraded to < 100 nm 
in thickness and resembled images from previous EM studies (see Fig. 2.1). The fol-
lowing year, Rehm et al. used a phosphate-buffered fixative containing Lanthanum, 
a trivalent cation that binds to glycoprotein structures [26]. The resulting images 
showed at 0.2- 0.3-JLm-thick glycocalyx in capillaries of guinea pig hearts. A subse-
quent study by Chappell et al. using the same technique revealed a glycocalyx 0.8-0.9 
Jtm in thickness in the human umbilical vein. 
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2.2 Intravital Microscopy 
Microvascular Hemodynamics 
Prior to the first direct in vivo visualization of the glycocalyx, several studies of 
microvascular hemodynamics provided indirect evidence for the existence of a layer 
rv 1 in thickness. Klitzman and Duling found a mean tube hematocrit, HT, of rv 10% 
in cremaster muscle capillaries of hamsters, while the mean systemic hematocrit, Hsys, 
in these animals was "' 53% [27]. Some reduction in HT relative to Hsys is expected as 
the distribution of red blood cells (RBCs) is not uniform over the vessel cross section; 
RBCs are generally concentrated towards the vessel centerline and there is a plasma-
rich zone near the vessel wall. Thus, the mean velocity of RBCs is greater than the 
mean blood flow velocity, resulting in value of HT that is less than the discharge 
hematocrit, Hn; this is known as the Fahrceus effect [28]. Assuming Hsys to be 
approximately equal to Hn, the ratio HT/ Hsys is not expected to be less than 0.5; 
this is much greater than the HT/ Hn "'0.2 observed in the experiments of Klitzman 
and Duling [6, 27]. To explain this discrepancy, they proposed a 1.2-,um-thick slow-
moving plasma layer at the EC surface. Desjardins and Duling measured similarly 
low values of HT and additionally found that Hn in the microvessels studied was 
similar to Hsys [29]. This indicated that the low values of HT observed were not the 
result of either arteriovenous shunting of red cells or an uneven distribution of red cells 
throughout microvascular networks. These results provided further indirect evidence 
of a slow-moving or immobile plasma layer at the blood-endothelium interface. In 
another study, Desjardins and Duling found that treatment with heparinase, resulted 
in a two-fold increase in capillary HT, suggesting that the treatment decreased the 
thickness of this plasma layer and increased the area available to flowing blood [30]. 
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While studying flow in microvascular networks, Pries et al. found further support 
for a substantially thicker glycocalyx than had been observed with EM. When the 
measured flow velocity and hematocrit in microvessels of the rat mesentery were com-
pared with the predictions of a mathematical model of the microvascular network, 
it was found that flow resistance in microvessels was substantially greater and more 
dependent on hematocrit than when measured in glass tubes [31, 32] . Further calcu-
lations indicated that a 1.1-JLm-thick immobile plasma layer at the EC surface would 
account for this discrepancy [6 , 32]. Additional experiments by Pries et al. showed 
that treatment with heparinase decreased microvascular flow resistance by an amount 
that was consistent with a 0.5 JLm reduction in the thickness of the glycocalyx, as 
predicted by mathematical models [6, 33]. Despite the differing approaches, the con-
clusions reached by Duling and co-workers and Pries et al. were strikingly similar, 
providing strong, but indirect evidence for a microvascular glycocalyx on the order of 
1 JLm in thickness. 
Dye-Exclusion 
The first direct in vivo visualization of the glycocalyx was achieved by Vink and 
Duling using the dye-exclusion method, which they developed and applied to capil-
laries of the hamster cremaster muscle. They measured the anatomical diameter of a 
capillary under brightfield microscopy (They also measured the anatomical diameter 
by staining the endothelial cells with a fluorescent membrane dye; this method gave 
similar results to measurements obtained using brightfield microscopy) and compared 
it with the functional diameter, which they defined as the area within the capillary 
lumen available for flow of various cellular and molecular components in the blood. 
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Bright field Fluorescence 
Figure 2.2: Images from the dye-exclusion experiments of Vink and Duling in capillaries of 
the hamster cremaster muscle [1] . The brightfield image on the left shows the full anatomical 
diameter of the vessel. The fluorescent image on the right shows the functional diameter, 
as measured by the width of the FITC-dextran column. The FITC-dextran exclusion zone 
near the vessel wall measures "' 0.4 J..Lm in thickness. (Reproduced from Vink and Duling, 
1996 [1], with permission from the publisher). 
The functional diameter was measured for white blood cells (WBCs), red blood cells, 
and a 70 kDa FITC-dextran plasma tracer. The mean anatomical diameter measured 
with brightfield microscopy was rv 5.1 J.Lm, whereas the width of the 70 kDa FITC-
dextran column, was only rv 4.3 J.Lm, revealing a layer rv 0.4- 0.5 J..Lm in thickness 
adjacent to the EC surface from which these inert plasma tracers were excluded. The 
functional diameter for RBCs was 3.9 ± 0.2 J.Lm. Interestingly, WBCs occupied the 
full anatomical diameter of the capillary, indicating that passing WBCs were large 
enough, and presumably stiff enough, to compress the glycocalyx in the tightly con-
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fined space of capillaries. Vink and Duling concluded that this layer represented the 
'true active interface' between flowing blood and the vessel wall. Using this same 
method, Henry and Duling demonstrated a similar exclusion zone for RBCs and 70 
kDa FITC-dextran in arterioles and venules up to 15 p,m in diameter [9]. 
Vink and Duling also showed that continuous epi-illumination of the 70 kDa FITC-
dextran column for a period of 1- 5 minutes (what they termed light-dye treatment) 
increased the functional diameter for RBCs and FITC-dextran and resulted in a 
60% increase in tube hematocrit [1]. This effect was abolished in the presence of 
SOD/CAT, suggesting that light-dye treatment generates free radicals that degrade 
the glycocalyx. Further experiments by Duling and co-workers explored the per-
meability of the glycocalyx to macromolecules of varying size and charge, and in-
vestigated the effects on the glycocalyx of treatments with hyaluronidase or TNF-a 
[2, 9, 34]. Application of the dye-exclusion method is limited to microvessels less than 
rv 15 p,m in diameter, due to out-of-focus light from the fluorescent FITC-dextran 
and Henry and Duling [9] showed that , due to diffraction near the vessel wall, the 
dye- exclusion method was limited to vessels with a small radius of curvature (i.e. 
those < 15 p,m in diameter) .optical difficulties near the vessel wall [7, 9]. The dye-
exclusion method does not provide any information regarding the flow conditions near 
the vessel wall or within the glycocalyx. 
p,-PIV and Microviscometric Analysis 
To investigate the endothelial glycocalyx and hemodynamics in larger microvessels, 
Damiano and coworkers developed a method combining their p,-PIV technique with 
microviscometric analysis. The p,-PIV technique uses dual-flash epi-illumination to 
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capture double images of fluorescent microspheres traveling in the midsagittal plane 
of the vessel [3, 5]. The distance between the two images of each microsphere and the 
dual-flash interval are then used to calculate microsphere velocities. Simultaneous 
capture of a brightfield image of the vessel wall allows for measurement of the radial 
position of the microsphere. Fluid particle velocities in the absence of microspheres 
are predicted from these measurements, using a three-dimensional analysis of fluid 
dynamics near the vessel wall [35]. These data can then be used to estimate the fluid 
velocity profile and the "effective hydrodynamically relevant glycocalyx thickness", 
defined as the thickness of the layer that significantly retards plasma flow. 
In the first application of p,-PIV, Smith et al. confined their analysis to the near-
wall region of the microvessel, considering only those microspheres that were within 2 
p,m of the vessel wall. The fluid mechanical analysis that they applied assumed that 
a uniform shear field prevailed throughout the near-wall region of the microvessel [3]. 
In this analysis, the glycocalyx was modeled as a Brinkman medium with hydraulic 
resistivity, K [35, 36]. Using a linear regression analysis of the fluid particle velocities 
to predict the slip velocity at the glycocalyx interface, the hydrodynamically relevant 
glycocalyx thickness was estimated for a range of K values. The estimated glycocalyx 
thickness was rv 0.33 p,m for the limiting case of K ----+ oo (i.e. corresponding to the 
situation of no flow through the layer) and rv 0.44 p,m when K = 108 dyn-sfcm4 
[3]. Thus, applying an assumption of an impermeable layer would result in a lower-
bound estimate of the glycocalyx thickness. A previous analysis by Damiano and 
Stace estimated the hydraulic resistivity of the glycocalyx to be between 1010 and 
1011 dyn-s/cm4 [37]. 
Subsequent p,-PIV studies have used the microvisometric method of analyzing the 
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data, which involves of full-field analysis of fluid particle velocities calculated from 
p,-PIV data collected over the entire cross-section of the microvessel [ 4, 5]. In this 
method, an iterative non-linear regression analysis is used to find the velocity profile 
and glycocalyx thickness resulting in the minimum least-square error in the fit to the 
fluid particle velocity data. The conservation of linear momentum is then applied 
to estimate viscosity, shear rate, and shear stress distributions over the vessel cross 
section, assuming that blood can be modeled as a continuous linearly viscous fluid 
with a spatially variable viscosity [4, 5, 38]. This method was validated by Long et al. 
in saline- and blood-perfused glass capillary tubes and in microvessels in vivo [4, 5] . 
The mean estimated hydrodynamically relevant glycocalyx thickness in venules of 
mouse cremaster-muscle venules was found to rv 0.5 p,m forK>= 109 ; this is rv 40% 
grater than the glycocalyx thickness estimated by near-wall analysis [3, 4]. Subse-
quent experiments by Potter and Damiano used p,-PIV and microviscometric analysis 
to investigate the glycocalyx on ECs cultured in cylindrical collagen microchannels, 
showing that under standard cell-culture condtions, the hydrodynamically relevant 
glycocalyx is absent in vitro [14]. 
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Chapter 3 
General Experimental Methods and Materials 
This chapter describes the methods that were common to all experiments performed. 
These include the preparation of animals for intravital microscopy, collection of fJ,-
PIV data, and microviscometric and statistical analysis of the data. Modifications 
to these methods or additional methods specific to each group of experiments are 
presented within the chapters describing those experiments. 
3.1 Preparation of Animals for Intravital Microscopy 
All animal experiments were conducted under a protocol approved by the Boston 
University Institutional Animal Care and Use Committee (protocol numbers 05-041 
and 08-031). Experiments were performed in male mice that were at least 8 weeks 
old and weighed at least 20 g at the time of the experiment. 
Anesthesia 
The animal was placed in an anesthesia induction chamber, where 3% isofluorane 
in oxygen was delivered at a flow rate of 500 ml/min using a vaporizer (Surgivet 
Model 100 Vaporizer, Smiths Medical PM, Inc., Waukesha, WI). After r--.J 2 minutes, 
when the mouse had lost its righting reflex and remained immobile, it was removed 
from the chamber and fitted with a nose cone to maintain anesthesia. Isofluorane 
concentration was then reduced to 1.5-2%. A patch of skin approximately 2.5 em 
in diameter was removed from the neck to expose the trachea and the mouse was 
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orotracheally intubated, with correct placement of the tube verified visually via the 
neck incision. At this time, the nose cone was removed and the mouse was connected 
to a ventilator (Inspira ASV, Harvard Apparatus, Holliston, MA), which continued 
to deliver the isofl.uorane/ oxygen mixture to maintain anesthesia. The respiration 
rate and tidal volume were determined automatically by the ventilator, based on the 
weight of the mouse. This procedure was completed in rv 10 minutes. 
Delivery of Experimental Reagents 
A jugular and/ or carotid cannula was used for blood sampling and infusion of experi-
mental reagents, such asP-selection antibody, fluorescent microspheres, and hyaluron-
idase. The vessels were exposed through the same incision used to establish the en-
dotracheal intubation. The proximal end of the exposed vessel was closed off with 
a microvascular arterial clamp. The distal portion of the vessel was tied off with 
5-0 silk suture to prevent retrograde bleeding. Heparinized PE-10 tubing was then 
inserted into the vessel through a small incision and stabilized with 5-0 silk suture 
and the clamp was then removed. Cannulation of each vessel was completed in 10-20 
minutes. 
Cremaster Muscle Preparation 
The mouse was transferred to a custom-made, heated Plexiglas platter with the ven-
tral side facing upwards. The right cremaster muscle was prepared for intravital 
microscopy as described in Baez [39] and in Ley et al. [40]. The testicle, epididymis, 
and associated structures were gently pushed from the scrotum up into the abdomen, 
by grasping the distal end of the scrotum with forceps and pushing the organs into 
the body. Approximately 1 em of the scrotum was then excised and the cremaster 
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muscle was exteriorized through this opening. There was minimal blood loss during 
this procedure. The cremaster muscle itself was then opened with a longitudinal in-
cision to allow separation of the testis from the muscle and surrounding membranes. 
Blood supply to the testis was occluded and the testis was either pinned to one side or 
pushed back into the peritoneal cavity. The cremaster muscle, while still attached to 
and blood perfused by the mouse, was then spread over a glass pedestal on the Plex-
iglas platter, allowing for illumination from below. Administration of a P-selectin 
antibody (20-40 J-LL , BD Biosciences, Inc.) helped systemically reduce leukocyte 
rolling and adhesion. This procedure was completed in rv 20- 30 minutes. 
Throughout preparation and subsequent intravital microscopy and collection of 
J-L-PIV data, the cremaster muscle was continuously superfused by a steady drip ( rv 5 
ml/min) of thermocontrolled, sodium-bicarbonate buffered physiological salt solut ion 
(composition in mmole/1: 131.9 NaCl, 4.6 KCl, 2.0 CaCb, 1.2 MgS04 , 20 NaHC03 ) 
equilibrated wit h 5% C02 in N2 . If necessary, succinylcholine (10 J-Lmole/1 , Sigma-
Aldrich Co., St. Louis, MO) was added to the superfusion solution to reduce spon-
taneous skeletal muscle contractions. The superfusion of the cremaster muscle was 
local; only the cremaster muscle preparation itself was affected by the paralytic in 
t he superfusion solut ion. Any spillover from the cremaster preparation was carefully 
collected and removed by a vacuum line. Thus, the preparation and solution were 
completely isolated from the rest of the animal. 
Hyaluronidase Treatment 
Enzymatic degradation of the glycocalyx followed the method described by Henry 
and Duling [9]. The mouse received a single bolus containing 100 U of Streptomyces 
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hyaluronidase (Sigma Chemical, St. Louis, MO) in phosphate buffered saline (PBS), 
through the jugular or carotid cannula, for a blood concentration of"' 93 U /ml. The 
enzyme was allowed to circulate through the blood stream for "' 1 hour before data 
collection. 
3.2 Micro-particle Image Velocimetry 
Micro-particle image velocimetry (fJr PIV) was performed using a variation on a pre-
viously described method [3] . The electrocardiogram (ECG) of the mouse was moni-
tored (Powerlab 4/30 with ML 136 Animal Bio Amp, ADinstruments, Inc., Colorado 
Springs, CO) throughout each experiment, which was terminated if the heart rate 
dropped below 250 beats per minute (BPM). Data was collected from a vessel seg-
ments 20-70 p,m in diameter that were in clear focus and were at least several diame-
ters downstream from any bifurcations or branches. By collecting data sufficiently far 
downstream from any flow disturbances, we were able to ensure that axisymmetric 
velocity distributions were present in all of the vessels that we analyzed. Since rolling 
or adherent leukocytes would break this symmetry, p,-PIV data were collected only 
when very few were present within the field of view; those that were present were 
located downstream from t he point of data collection. 
Intravital microscopic observations were made on a Zeiss microscope (Axioskop 
II, Carl Zeiss, Inc., T hornwood, NY) with a 63x saline immersion objective (NA 
1.0), focused on the midsagittal plane of the vessel. This was defined as the focal 
plane where the contrast of the edge of the intraluminal wall reversed [41]. Neutrally 
buoyant fluoresbrite YG microspheres or polychromatic red microspheres ("' 0.5 p,m 
diameter, p =1.05 gjcm3 , Polysciences, Inc., Warrington, PA) were suspended in 
18 
saline (1- 3 drops/ml) and then sonicated for 10 minutes. A small volume ( < 0.05 
ml) of the microsphere solution was slowly injected through the jugular or carotid 
cannula until rv 10-20 microspheres per second passed through the vessel. Recordings 
were then made with a CCD camera (Sensicam QE, Cooke Corp., Romulus, MI) 
connected to a G5 Power Mac (Apple, Inc., Cupertino, CA). A Dualview beam splitter 
(Optical Insights, LLC, Santa Fe, NM) separated infrared transillumination from the 
fluorescent microsphere image, allowing for simultaneous acquisition of the vessel 
wall and microspheres. Stroboscopic double-flash (4-9 ms apart, DPS-1 Video, Rapp 
OptoElectronic GmbH, Hamburg, Germany) epi-illumiation resulted in a dual image 
of each microsphere. The flash-time interval for flr PIV recordings was chosen such 
that the two images of a microsphere were 3-10 J-Lm apart and appeared as a double 
exposure on the same digital image. A minimum of 300 images were captured from 
each vessel and processed with IP Lab/iVision-Mac software (BioVision Technologies 
Inc., Exton, PA). A single frame of J-L-PIV data is shown in Fig. 3.1(A) . The fluorescent 
image is on the left, where double-images of two microspheres can be seen, encircled 
in white. The brightfield image of the vessel is on the right, with the direction of flow 
indicated by the arrow. 
3.3 Data Analysis 
Microviscometric Analysis 
Images were analyzed with the public domain software ImageJ (available at : 
http : / /rsbweb.nih.govjij/), as previously described [3]. The brightfield and fluo-
rescent images were merged so that both the microspheres and the vessel wall were 
clearly visible in the combined image, as shown in Fig. 3.1(B). This is the same frame 
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F igure 3.1 : ,u-PIV data from a single venule in a WT mouse under control conditions. 
Shown in (A) are the separate fluorescent (left) and brightfield (right) images. The merged 
image is shown in (B). The full data set is shown, plotted across the vessel diameter in (C). 
Axisymmetry allows for the data to then be folded in half before it is monotonically filtered 
(D, closed circles indicate data points remaining after the monotonic filter is applied). 
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of data as shown in Fig. 3.1(A). Note that the microsphere that is closer to the ves-
sel wall (encircled with a solid line) has a lower velocity than the microsphere that 
is nearer the vessel centerline (encircled with a dashed line). After the images are 
merged, the distance between the two images of the doubly exposed microsphere were 
measured, as was the shortest distance between the microsphere center and the vessel 
wall. These measurements were obtained for at least 40 microspheres in each vessel. 
The resulting data distribution for each vessel was axisymmetric and the data was 
then folded onto to one half of the vessel cross-section. Only microspheres traveling 
in the midsagittal plane of the vessel were of interest for this analysis; although not 
all recorded beads travel in the midsagittal plane. A microsphere in the midsagittal 
plane travels faster than any other microsphere at that same measured radial loca-
tion; therefore, only the fastest beads at a given radial location were considered in the 
analysis. A previously described monotonic filter [3, 4] was used to determine which 
microspheres met these criteria. A full data set is shown in Fig. 3.l(C), with the 
velocity of each microsphere plotted vs. its position relative to the vessel centerline. 
Note the axisymmetric distribution of the data. Fig. 3.1(D) shows the same data set 
after it has been folded onto one half of the vessel cross-section. 
The monotonically filtered subset of data was then analyzed using Mathemat-
ica software (Wolfram Research Inc., Champaign, IL). For each microsphere, the 
predicted velocity of a fluid particle at that radial location, in the absence of the mi-
crosphere, was calculated, using a three-dimensional analysis of fluid dynamics near 
the vessel wall [35]. A fitting function for the velocity profile, consisting of a con-
stant term, a quadratic term, and a growing and a decaying exponential term, was 
then used to perform a nonlinear regression analysis to determine the values of two 
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constants that minimize the least-squares error in the fit to the fluid particle velocity 
data, for a given trial glycocalyx thickness. Further details regarding this regression 
analysis are given ·by Damiano et al. [4]. Validation of microviscometric analysis in 
mouse cremaster muscle venules in vivo and in glass capillaries perfused with red cells 
suspended in plasma is provided by Long et al. [5]. 
To estimate the hydrodynamically relevant glycocalyx thickness, the best fit to 
the J-t-PIV data was calculated for a range of trial glycocalyx thicknesses, with the 
maximum possible thickness determined by the data point nearest to the vessel wall. 
The variation in the least-squares error, E, associated with the fit to the J-t-PIV data 
was used to track the quality of the fit relative to each trial glycocalyx thickness. 
The minimum in this variation in E corresponds to the best fit of all trials and pro-
vides our estimate for the hydrodynamically relevant glycocalyx thickness. Defining 
a normalized least-squares error, E* = E/ Emin, where Emin is the minimum value of 
E, the estimated hydrodynamically relevant glycocalyx thickness corresponds to the 
trial thickness associated with E* = 1. Flow through the glycocalyx was assumed to 
be negligible ( K ----+ oo), which results in a lower-bound estimate of the glycocalyx 
thickness [3 , 4] . In previous studies, Damiano and Stace estimated the hydraulic re-
sistivity of the glycocalyx to be between 1010 and 1011 dyn-s/cm4 [37] and Damiano 
et al. found that, forK> 109 dyn-s/cm4 , the glycocalyx thickness estimated by mi-
croviscometric analysis was insensitive to K [4] . Fig. 3.2(A) shows the error curve for 
the data presented in Fig. 3.1, with the minimum indicated by the black arrow. The 
estimated glycocalyx thickness, R- a, for this vessel is 0.44 J-tm where R is the radius 
of the vessel and, a is the distance from the vessel centerline to the blood-glycocalyx 
interface. Fig. 3.2(B) shows the corresponding axisymmetric velocity profile, plotted 
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Fig u re 3. 2: Results of microviscometric analysis of the f.,l-P IV data shown in Fig. 3.1. The 
variation, relative to trial glycocalyx thicknesses, in the normalized least-squares error, E*, 
associated with the fit to the f.,l-PIV data is plotted in (A) . In this venule, the estimated 
hydrodynamically relevant glycocalyx thickness is 0.44 f.,lm, as indicated by the black arrow. 
Plotted in (B) is the corresponding axisymmetric velocity profile (curve), along with the 
monotonically filtered subset of data (dots) that was used in the analysis; the mean veloc-
ity, V, is 1,400 f.,lmjs. The shaded region near the vessel wall represents the endothelial 
glycocalyx. The local blood viscosity profile, 1-l(r), relative to the viscosity at the blood-
glycocalyx interface, 1-l(a) , is plotted in (C). The shear-rate (solid line) and shear stress 
(dashed line) profiles are shown in (D); 11'1 = 1,100/s is the magnitude of the shear-rate at 
the blood-glycocalyx interface. 
23 
along with the monotonically filtered subset of 11-PIV data. Once this velocity profile, 
Vfit, has been determined, the viscosity, J.L(r), shear-stress, r(r), and shear-rate, )'(r), 
profiles can be calculated using Eqn. 3.1- 3.3 (Damiano et al. [4]). 
J.L(r) 
f.LR 
r (dvtitfdr)lr=R 
R dvJitfdr 
. ( ) dvfit 
"'(T =--
dr 
r(r) = J.L(rh(r) 
(3.1) 
(3.2) 
(3.3) 
Here, r is the distance from the vessel centerline and 0 < r < R. When calculating 
the shear-stress profile, it is assumed that J.L( a) = /1plasma· Empirical support for this 
assumption was provided by Long et al. [5] . The viscosity, shear stress, and shear 
rate profiles are plotted in Fig. 3.2(C) and (D) . 
Statistical Analysis 
Results for each experimental group are presented as mean ± one standard devia-
tion (SD). A two-tailed independent t-test was used to compare groups. Differences 
between groups were considered to be significant if p < 0.05. 
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Chapter 4 
The G lycocalyx in Arterioles 
Portions of the material presented in this chapter originally appeared in [42]: Savery 
MD, Damiano ER. The endothelial glycocalyx is hydrodynamically relevant in arte-
rioles throughout the cardiac cycle. Biophysical Journal. 2008;95(3):1439-1447. It is 
reprinted here with the permission of the publisher, Elsevier. 
4.1 Introduction 
Much attention has recently been focused on the role of the endothelial-cell glycoca-
lyx in a variety of processes in cardiovascular physiology and pathophysiology includ-
ing inflammation, microvascular permeability, endothelial-cell mechanotransduction, 
atherosclerosis, and diabetes [7, 16, 18, 43]. The fact that the native endothelial gly-
cocalyx in vivo not only excludes macromolecules and flowing red blood cells from 
near-wall regions of microvessels < 15 p,m in diameter [1, 9, 34], but also retards 
plasma flow through these same regions of venules and eliminates fluid shear stress 
on the surface of venular endothelium has now been well established [3- 5, 14]. It has 
not been demonstrated, however, if the endothelial glycocalyx is indeed ubiquitous 
throughout the microcirculation in vivo or if it is preferential to small microvessels 
and post-capillary venules. In particular, the hydrodynamical relevance of the en-
dothelial glycocalyx in arterioles > 15 p,m in diameter has not been investigated in 
vivo. Furthermore, the presence of cardiac-induced pulsatility in arterioles, which is 
largely absent in post-capillary venules due to dampening effects throughout the capil-
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lary bed, may cause periodic perturbations in the glycocalyx throughout the cardiac 
cycle, which could influence the hydrodynamic environment near the endothelium. 
The differing hemodynamic environments between arterioles and venules may influ-
ence or even determine the extent to which the glycocalyx appears on arterial versus 
venular endothelium, which may in turn have important implications for endothelial 
mechanotransduction, angiogenesis, and atherosclerosis. 
From p,-PIV data of the instantaneous speeds and radial positions of fluorescent 
microspheres (rv 0.5 p,m diameter) traveling in an optical section through the median 
plane of venules, Damiano and coworkers [4, 5, 14] were able to extract velocity profiles 
over the cross-section of venules "' 20-100 p,m in diameter. With the assumption 
that blood flow in microvessels > 20 p,m in diameter can be well approximated by a 
homogeneous, continuous linearly viscous fluid with spatially variable viscosity [4, 5, 
38], the conservation of linear momentum and the constitutive equation for a linearly 
viscous fluid were used to estimate radial distributions in viscosity, shear rate, and 
shear stress and to probe the existence of a hydrodynamically relevant glycocalyx 
on the luminal surface of venules in vivo before and after light-dye and enzymatic 
treatments to degrade the glycocalyx. In addition, this approach, which Long et 
al. [5] termed 'microviscometric analysis,' allowed for accurate estimates of pressure 
gradient and relative apparent viscosity in vivo. The effectiveness of microviscometry 
was validated in smooth cylindrical glass tubes (rv 30 to 80 p,m in diameter) perfused 
with red cells suspended in plasma and in blood-perfused post-capillary venules in 
vivo ( rv 20- 60 p,m in diameter) before and after isovolemic hemodilution [5]. 
Using microviscometry, together with a detailed three-dimensional analysis of the 
fluid dynamics around the microsphere and throughout the glycocalyx [35], Damiano 
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and coworkers were able to show that the only possible velocity distribution within 
the glycocalyx that was consistent with the f-l-PIV data had to be highly nonlinear 
and therefore indicative of a region near the vessel wall that significantly retards 
plasma flow [3- 5, 14]. They showed that in mouse cremaster-muscle venules ,......, 20-
100 f-Lm in diameter, this region extended ,......, 0.5 f-Lm from the vessel wall in control 
vessels, and was termed the "effective hydrodynamically relevant thickness" of the 
glycocalyx, where this quantity is understood to represent an average value that is 
characteristic of an inherently heterogeneous endothelial glycocalyx. After light-dye 
treatment to degrade the glycocalyx, the hydrodynamically relevant thickness was 
reduced to ,......, 0.2 f-Lm [4], whereas it was essentially absent after enzymatic digestion 
with hyaluronidase [14]. 
The main technical challenge in applying microviscometric analysis to arteriolar 
blood flow arises as a result of the flow pulsatility present in these vessels [ 44, 45]. 
In order to extract data from the same instantaneous velocity profile, we exploit the 
periodicity in the flow regime in these vessels and synchronize M-PIV data acquisition 
with the animal's electrocardiogram (ECG). To do this, we adapt some of the methods 
developed by Tangelder et al. [44], in which the translational speeds of fluorescently 
labeled platlets were tracked in arterioles in vivo and recorded on video tape. Rather 
than using platelets, which are too large to provide the spatial resolution necessary 
to accurately extract the velocity distribution through the plasma-rich zone near the 
vessel wall, we use neutrally buoyant fiuorescently labeled polystyrene microspheres 
,......, 0.5 f-Lm in diameter. As shown below, with a simple generalization of microvisco-
metric analysis, all of the methods that we have developed to study microvascular 
hemodynamics in venules [3- 5, 35], can be applied in a straightforward manner to 
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the present study in arterioles. 
Considerations and methods for generalizing our microviscometric method to the 
analysis of hemodynamics in arterioles are detailed below. This generalized analysis 
is used to estimate the effective hydrodynamically relevant thickness of the endothe-
lial glycocalyx in arterioles ( rv20- 70 JJ-m in diameter) before and after hyaluronidase 
treatment to degrade the layer. We further examine the influence of flow pulsatility 
on the hydrodynamically relevant glycocalyx thickness by comparing results obtained 
from JJ--PIV data acquired from the same arteriole at four distinct t ime points in the 
cardiac cycle. 
4.2 Methods and Materials 
Intravital microscopy, JJ--PIV, and microviscometric analysis were performed as de-
scribed in Chapter 3, with modifications required for the application to arterioles 
described below. Experiments were performed in wild-type C57bl/6 male mice that 
were at least 8 weeks old and weighed 20-25 grams. Mice were obtained from Charles 
River Labs (Wilmington, MA) or J ackson Labs (Bar Harbor, ME). Microviscometric 
analysis was performed with Mathematica software version 4. 
Data Collection at Specific Time Points in the Cardiac Cycle 
The ECG was used to trigger the camera and stroboscopic flash, in order to restrict 
data acquisition to a specific t ime point in the cardiac cycle. The first set of data 
from each arteriole was collected 10 ms after peak systole. In a subset of arterioles, 
five sets of data were recorded, with each data set being collected at a single t ime 
point in the cardiac cycle. The first data set (A) was recorded 10 ms after peak 
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Figure 4.1: Data collection at specific time points in the cardiac cycle. The first set of 
data from each arteriole (A) was collected 10 ms after peak systole. In a subset of arterioles, 
data was collected at three additional time points (B, C, D), such that the four data sets 
were equally spaced throughout the cardiac cycle. 
systole. The following three data sets (B, C, and D) were each collected at specific 
time points in the cardiac cycle, such that the four data sets were equally spaced 
throughout the cycle, as shown in Fig. 4.1. A final data set (A') was collected at 
the same time point in the cardiac cycle as the first (A), in order to quantify any 
changes in hemodynamics that may have occurred during the data collection period. 
The total time required to collect these five data sets was rv 10- 15 minutes. 
29 
Microviscornetric Analysis of Arteriolar Blood Flow 
The governing equations used in microviscometry were derived for steady, axisymmet-
ric, parallel flows in a cylindrical tube [4, 5]. However, these conditions can be relaxed 
to allow the approach to extend to unsteady flow regimes. For the case of an unsteady, 
instantaneously fully developed, axisymmetric parallel flow of an incompressible con-
tinuum fluid in a cylindrical tube of radius R, the only non-vanishing component of 
the deviatoric stress tensor, written in terms of the cylindrical coordinates (r, e, z), 
is the shear stress component, Trz· Furthermore, from the radial momentum equa-
tion, the axial component of the pressure gradient, apjaz, is a function only of time. 
Consequently, the axial momentum equation reduces to 
avz 1 a ap 
p-a - --a (rTrz) = -a = func(t) only, 0 < r < R, 
t r r z 
(4.1) 
where pis the fluid density and v2 (r, t) is the instantaneous axial velocity component 
of the fluid. Integrating twice with respect to r provides 
where 
rap p aq 
Trz = 2 az + 27rr at' 0 < r < R, 
r 
q(r,t) = 21r j v2 (r,t)rdr, 0 < r < R, 
0 
(4.2) 
( 4.3) 
is the instantaneous volume flow rate through the circular cross-sectional area that is 
of radius r and is centered along the tube axis. 
The importance of the inertial term can be readily ascertained by nondimensional-
izing Eq. 4.2. If the radial and axial coordinates are nondimensionalized with respect 
to the tube radius, R, and p and Trz are nondimensionalized with the same charac-
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teristic pressure, f J.-lp, where J.-lp is the dynamic viscosity of blood plasma and f is the 
characteristic forcing frequency (in Hz) of the pressure gradient, then Eq. 4.2 takes 
the following dimensionless form 
* r* op* + St oq* 0 < r* < 1' Trz = 2 OZ* r* ot* ' ( 4.4) 
where an asterisk denotes a nondimensional variable. In Eq. 4.4, the dimensionless 
volumetric flow rate q* = qj(R3 f) and St = pR2 f j /-lp is the Stokes number, which 
characterizes the ratio of unsteady inertial forces to viscous forces. If T:z' op* I 8 z*' 
and oq* j 8t* are all of the same order of magnitude, then the relative importance of 
the inertial term in Eq. 4.4 can be assessed solely by considering the magnitude of the 
Stokes number. For the range of arteriolar diameters that we consider in this study, 
7 x 10-4 < St < 9 x 10-3 , assuming a maximum heart rate of r-v 500 beats/min (BPM). 
Thus, it is reasonable to neglect unsteady inertial forces in these vessels and to take 
St = 0. In this case, viscous forces and pressure forces are instantaneously in balance 
at any moment in the cardiac cycle, which implies that microviscometric analysis 
can be applied instantaneously at any moment in the cardiac cycle. Accordingly, we 
are justified in generalizing the steady-state microviscometric analysis of Damiano et 
al. [4], to obtain the unsteady viscosity distribution, shear stress distribution, and 
pressure gradient given, respectively, by 
J.-L(r , t) 
f.-Lp 
r ( OVz/ or) [r=R 
R ovz/or 
r /y(R, t) 
R /y(r, t) ' 0 < r < R, 
Trz(r , t) = p(r, t) /y(r, t) = /-lp ~ /y(R, t), 0 < r < R, 
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(4.5) 
(4.6) 
and 
8p 2pp 0 
az = R !(R, t), (4.7) 
where the shear rate and axial velocity profile are kinematically related according to 
avzf8r = ~(r, t). 
These results can readily be applied to straight cylindrical sections of glycocalyx-
lined microvessels by simply substitut ing for the tube radius, R, in Eqs. 4.5- 4. 7 t he 
radial coordinate location, a, of the blood- glycocalyx interface. This is described in 
more detail for the case of steadily perfused glycocalyx-lined microvessels in Damiano 
et al. [4] . 
4.3 Results 
The combined brightfield and fluorescent image for a single frame containing p-PIV 
data in an arteriole is shown in Fig. 4.2. The vessel wall is clearly visible, along with 
dual images of two microspheres. Figure 4.3 shows an example of a full p-PIV data 
set obtained from an arteriole before filtering t he data for monotonicity. It is evident 
from the distribution of p-PIV data in t his vessel that the velocity profile is essentially 
axisymmetric. 
Estimated Mean Glycocalyx Thickness in Arterioles 
Microviscometric analysis of our p-PIV data, similar to those shown in Figs. 4.4 and 
4.5 and Tab. 4.1 , consistently revealed the presence of a hydrodynamically relevant 
surface glycocalyx in all of the arterioles that we examined prior to enzyme treatment 
with hyaluronidase. In arterioles rv 20-70 pm in diameter (39.3 ± 8.8 pm, 23.3-61.2 
pm n = 20), the mean hydrodynamically relevant glycocalyx t hickness was estimated 
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Figure 4.2: Combined bright-field and fluorescent image in a 46-p,m-diameter arteriole in 
the mouse cremaster muscle in vivo. Dual images of two microspheres (encircled in white) 
are separated in time by the double-flash interval. The direction of flow in this image is 
from left to right. The white arrow indicates the anatomical diameter of the microvessel. 
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Figure 4.3: The unfiltered p,-PIV data set from a 34-p,m-diameter arteriole in the mouse 
cremaster muscle in vivo. The corresponding error curve, along with the estimated velocity, 
viscosity, shear-rate, and shear-stress profiles are shown in row C of Figs. 4.7 and 4.8 . 
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Figure 4.4: Results from a 42.1-p,m-diameter arteriole under control conditions in the 
mouse cremaster muscle in vivo. Shown in (A) are intravital fluorescent p,-PIV data (sym-
bols) collected at the same time point in the cardiac cycle and the corresponding predicted 
axisymmetric velocity profile extracted from the data (curve). The shaded region near the 
vessel wall represents the endothelial glycocalyx. Shown in (B) is the variation, relative to 
trial glycocalyx thicknesses, in the normalized least-squares error, E*, associated with the 
fit to the u-PIV data shown in (A I. The estimated hvdrodvnamicallv effective thickness 
I \. ,/ V V V 
of the glycocalyx corresponds to the value of R - a associated with the local minimum in 
this curve. In this arteriole, the estimated glycocalyx thickness is 0.43 p,m, as indicated 
by the black arrow. The local blood viscosity profile, p,(r), relative to the viscosity at the 
blood-glycocalyx interface, p,( a), is plotted in (C). The shear-rate (solid line) and shear-
stress (dashed line) profiles are shown in (D). Estimated hemodynamic parameters for this 
arteriole are given in Table 4.1 . 
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Figure 4.5: Results from a 29.7-p,m-diameter arteriole after systemic hyaluronidase treat-
ment in the mouse cremaster muscle in vivo. Same interpretation as Figure 4.4. Note 
that in this arteriole, no hydrodynamically relevant glycocalyx remains after hyaluronidase 
treatment. Estimated hemodynamic parameters for this arteriole are given in Table 4.1. 
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Table 4 .1: Hemodynamic parameters for the arterioles shown in Figs. 4.4 and 4.5 . Tab-
ulated are the measured vessel diameter, D; the estimated glycocalyx thickness, R- a; 
the maximum, Vmax, and average Vavg, velocities of the predicted axisymmetric velocity 
profile; the magnitude of the predicted axial pressure gradient, J8pj8zJ; the magnitude of 
the predicted shear stress, jT(a)J, and shear rate, Ji'(a)J, at the blood-glycocalyx interface; 
the ratio of the predicted interfacial shear rate, i'( a), to the wall shear rate, )'p ( R), of a 
Poiseuille flow having a centerline velocity equal to Vmaxi and the predicted relative appar-
ent viscosity, rJrel· 
control hyaluronidase 
D (fbm) 42.1 29.7 
R- a (Ibm) 0.43 0.0 
Vmax (fbm/s) 5,130 4,040 
Vavg (Ibm/ S) 3,270 2,850 
jopjozl (dyn/cm3) 36,300 72,500 
jT(a)i (dynjcm2 ) 39 54 
)'(a) (s-1 ) 3,100 4,400 
)'(a)/i'P(R) 6.5 8.1 
'TJrel 3.4 5.7 
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Figure 4.6: Hydrodynamically relevant glycocalyx thickness (mean and SD) as determined 
by microviscometric analysis in venules and arterioles in vivo, before and after treatment 
with hyaluronidase. Experiments were performed with 19 wild type mice in venules and 
arterioles (20- 70 J..Lm in diameter). The mean hydrodynamically relevant glycocalyx thick-
ness was found to be 0.51 ± 0.15 J..Lm in control venules (n = 9) and 0.38 ± 0.11 J..Lm in 
control arterioles (n = 20) . The mean hydrodynamically relevant glycocalyx thickness af-
ter hyaluronidase treatment was found not to be significantly different from zero in either 
venules or arterioles. Symbols denote a significant difference via a non-directional t-test 
(p < 0.025). Note the significant difference between the glycocalyx thickness in venules and 
arterioles in vivo. 
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to be 0.38 ± 0.11 f-Lm (0.15- 0.61 f-Lm), as compared with 0.51 ± 0.15 f-Lm (0.26-0.75 
f-Lm, n = 9) found in venules rv 20- 70 f-Lm in diameter (40.9 ± 14.6 f-Lm, 25 .9-63.6 
f-Lm). This difference was found to be statistically significant (p = 0. 025). The 
mean hydrodynamically relevant glycocalyx thickness after hyaluronidase treatment 
to degrade the layer in both arterioles and venules was found not to be significantly 
different from zero (0.03 ± 0.04 f-Lm, 0.00- 0.11 f-Lm, n = 6 venules; 0.01 ± 0.02 f-Lm, 
0.00- 0.07 f-Lm, n = 8 arterioles). 
Influence of Hemodynamic Parameters on Mean Glycocalyx Thickness 
In a subset of the arterioles studied (n = 8), M-PIV data were collected at four time 
points in the cardiac cycle. Example results from one such case are shown in Figs. 4. 7 
and 4.8 and Tab. 4.2. Data sets A and A' were collected 0.01 s after peak systole. 
Data sets B, C, and D, were respectively collected at 0.048, 0.085, and 0.123 s after 
peak systole. The five data sets were collected over a period of rv 15 minutes, with set 
A being collected first and set A' being collected last. Over this period, the heart rate 
of the mouse was rv 400 BPM. Notice that throughout the cardiac cycle there is little 
change in the thickness of the glycocalyx. Also note that the maximum observed 
centerline velocity occurs in data set C, and is rv 50% greater than the centerline 
velocity observed in data set A. There was no statistically significant difference in the 
mean hydrodynamically relevant glycocalyx thickness between any two of the four 
different time points in the cardiac cycle (see Fig. 4.9) . Furthermore, there appeared 
to be essentially no correlation between the hydrodynamically relevant glycocalyx 
thickness and either the centerline velocity (correlation coefficient, {2 = -0.12), the 
centerline viscosity (Q =0.23), the interfacial shear rate (Q = -0.10), or the interfacial 
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shear stress (Q = 0.09). In addition to the lack of correlation with hemodynamic 
parameters, we found virtually no correlation between the hydrodynamically relevant 
glycocalyx thickness and the vessel diameter in either venules (Q = 0.25) or arterioles 
(Q = -0.18) rv 20-70 J-Lm in diameter. 
Due to the finite time required to acquire the J-L-PIV data ( rv 15 minutes total for all 
four time points chosen within the cardiac cycle), it is possible that the prevailing flow 
conditions drifted somewhat during data collection. In an attempt to quantify these 
changes, the first and last data sets (A and A') in each vessel were collected at the same 
time point in the cardiac cycle. Differences between the estimated distributions in 
velocity, viscosity, or shear rate found at A and A' would suggest that the overall flow 
conditions changed during the period of data acquisition. On average the predicted 
centerline velocity, Vmax, and interfacial shear rate, ry(a), at A' were rv 10% less than 
those at A, while the predicted centerline viscosity was unchanged between the two. 
Comparatively, the average differences between the maximum and minimum predicted 
centerline velocity, interfacial shear rate, and centerline viscosity were, respectively, 
50%, 80%, and 70% when data taken at all points in the cardiac cycle were considered. 
This indicates that any drift in the overall flow conditions during the finite time needed 
to collect data was, on average, smaller than were the pulsatile changes in the flow 
observed throughout the cardiac cycle. Any drift in overall flow conditions can be 
attributed to changes in hemodynamics upstream or downstream from the point of 
data collection, including, but not limited to, changes in flow rate, feed hematocrit, 
and vasomotor tone. 
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Figure 4. 7: Results from a 34.4-p,m-diameter arteriole under control conditions at four 
time points in the cardiac cycle. Shown in the left column are intravital fluorescent p,-PIV 
data (symbols) and the corresponding predicted axisymmetric velocity profiles (curves) 
extracted from the data. The inset shows the time point in the cardiac cycle where the 
data were collected (vertical arrow). The shaded region near the vessel wall represents the 
endothelial glycocalyx. Shown in the right column is the corresponding variation in the 
normalized least-squares error, E*, associated with the fit to the p,-PIV data shown in the 
left column. The estimated glycocalyx thickness, R - a, is indicated by the arrow. 
Table 4.2: Hemodynamic parameters for the arteriole shown in Figs. 4.7 and 4.8. Tab-
ulated are the diameter, D = 2R, of the arteriole and the estimated glycocalyx thickness, 
R - a, associated with each data set, as well as the corresponding values of the same 
hemodynamic parameters shown in Table 4.1. 
D = 34.4 J.Lm A B c D A' 
R- a (p,m) 0.44 0.44 0.47 0.48 0.44 
Vmax (p,mjs) 2,480 2,580 3,740 3,340 2,790 
Vavg (p,mjs) 1,530 1,660 2,320 1,990 1,760 
ldp/dzl (dyn/cm3 ) 24,900 32,000 38,400 31,300 18,000 
/T(a)i (dynjcm2) 22 28 34 28 16 
h'(a) I (s- 1) 1,700 2,200 2,700 2,200 1,300 
"f(a)f"fp(R) 6.2 7.7 6.4 5.8 4.0 
'Tlrel 3.0 3.2 2.9 2.8 2.4 
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,u-PIV data and estimat ed velocity profiles shown in Fig. 4.7. Shown in the left column are 
the local blood viscosity profiles, relative to plasma viscosity. Shown in the right column 
are the shear rate (solid line) and shear stress (dashed line) profiles. 
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Figure 4.9: Hydrodynamically relevant glycocalyx thickness (mean and SD) as determined 
by microviscometric analysis in arterioles in vivo at four t ime points in the cardiac cycle 
(n = 8) . Experiments were performed in arterioles (20- 70 p,m in diameter) of five wild type 
mice. The mean hydrodynamically relevant glycocalyx thickness was found to be 0.42±0.09 
p,m at point A, 0.44 ± 0.07 p,m at point B, 0.47 ± 0.10 p,m at point C, 0.42 ± 0.09 p,m at 
point D, and 0.40±0.09 p,m at point A'. These differences were found not to be statistically 
significant (p > 0.2). 
4.4 Discussion 
These results provide the first direct in vivo evidence for the existence of a hydrody-
namically relevant glycocalyx in arterioles> 15 p,m in diameter. While the mean layer 
thickness found is 5-10-fold greater than most images of the structure obtained using 
electron m icroscopy [25, 46], at rv 0.4 p,m, it is nevertheless statistically significantly 
thinner than the mean hydrodynamically relavent glycocalyx thickness observed in 
similarly sized venules from the same tissue. A difference in mean glycocalyx thick-
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ness between venules and arterioles of rv 0.1 p,m may indeed be within the resolution 
of microviscometry. If one assumes that the hydrodynamically relevant glycocalyx 
is completely degraded after hyaluronidase treatment, then the positive mean layer 
thickness found in venules and arterioles after enzymatic degradation ( rv 0.02 p,m) 
could be regarded as a measure of the resolution inherent to the method's ability 
to estimate mean layer thickness. If t his is true, then a difference of 0.1 p,m in the 
mean hydrodynamically relevant glycocalyx thickness between venules and arterioles 
should be detectable using this approach. 
This difference in mean hydrodynamically relevant glycocalyx thickness between 
venules and arterioles could be attributable to hemodynamic differences between these 
vessels . However, as well as there being essentially no correlation between the hy-
drodynamically relevant glycocalyx thickness and either the centerline velocity, Vmax, 
the centerline viscosity, f.tmax, the interfacial shear rate, )'(a), or the interfacial shear 
stress, T(a), our results show there to be no statistically significant difference in any 
of the hemodynamic quantities between the population of arterioles that we observed 
or a similar population of venules 20-70 p,m in diameter. Furthermore, our results 
show that even when centerline velocity varies by as much as "'50% within the car-
diac cycle, we see no statistically significant difference in the mean hydrodynamically 
relevant glycocalyx thickness between any two t ime points in the cardiac cycle, sug-
gesting that the hemodynamic environment is not a strong determinant of the mean 
glycocalyx thickness. These results t herefore suggest that there may be a phenotypical 
difference between arteriolar and venular endothelium that might influence regulation 
of the glycocalyx and explain the difference observed in the mean hydrodynamically 
relevant glycocalyx thickness in arterioles and venules. 
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The fact that in all of the control arterioles that we observed, microviscometry 
revealed a hydrodynamically relevant glycocalyx, which was typically"' 0.4 f.J,m thick 
throughout the cardiac cycle, implies a vanishingly small fluid shear stress and fluid 
shear rate on t he luminal surface of arteriolar endothelial cells. This was first illus-
trated experimentally by Smit h et al. [3] using f.J,-PIV limited to particle tracers in 
t he plasma-rich region near the vessel wall in post -capillary venules. They showed 
that a linear fit to these f.J,-PIV data consistently revealed a negative velocity when 
this line was extrapolated to the vessel wall, and concluded that, in order to satisfy 
the no-slip condition on the luminal endothelial-cell surface, a strongly exponential 
rather t han linear velocity distribution must exist within t he glycocalyx itself. This 
exponential behavior is consistent with the velocity profile that would arise t hrough 
a porous material, such as a Brinkman medium [7, 35, 36, 47-49]. Damiano et al. [4] 
subsequently showed, using full-field f.J,-PIV data collected over the entire cross-section 
of post-capillary venules, that microviscometric analysis (as was used in this study) 
provided an improved estimate of the hydrodynamically relevant glycocalyx thick-
ness in venules, since it relaxed the requirement of a linear velocity distribution 
throughout the plasma-rich region near the vessel wall. The proposed exponential 
velocity distribution across t he glycocalyx corresponds to a heavily retarded flow of 
plasma throughout glycocalyx, and particularly near the luminal endothelial-cell sur-
face. Thus, on the basis of our results, endothelial cells in arterioles, like venules, are 
essentially bathed in a quiescent fluid that does not circulate or turn over throughout 
the cardiac cycle. Convection is absent and transport of small molecules is diffusion 
limited. The fluid shear rate, and as a consequence, the fluid shear stress, vanishes on 
the luminal endothelial-cell surface. Thus, the fluid shear stress from the prevailing 
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flow in the vessel lumen is transferred in the form of mechanical stress to the solid 
matrix components of the glycocalyx [36]. This stress in the solid components of 
the glycocalyx can be readily transferred, through transmembane domains of core 
proteins in the glycocalyx, to the endothelial-cell cytoskeleton [3, 17]. 
This revised perspective on our understanding of the mechanism for stress trans-
mission to vascular endothelium, which was postulated on theoretical grounds by 
Damiano et al. [36] and later supported experimentally in venules by Smith et al. [3] 
and in arterioles by the present study, certainly has important implications for endo-
thelial-cell mechanotransduction and atherosclerosis. Even before this in vivo confir-
mation in arterioles was made, the role of the glycocalyx in endothelial-cell mechan-
otransduction was the focus of a variety of recent studies [11, 16-18, 50]. In each of 
these studies it was tacitly assumed that the in vivo results previously reported on 
the glycocalyx in capillaries and venules extended to arterioles. However, if further 
such studies are to be pursued, it is essential that the in vivo results of the present 
study be reported, particularly since physiological and pathophysiological processes 
that are preferential to arterioles might be determinants or consequences of the state 
of the glycocalyx on arteriolar endothelium. 
Our hemodynamic results for Vavg and Vmax in control arterioles were in good 
agreement with the results of Tangelder et al. [44] in terms of Vmax as well as the ratio 
Vmax/Vavg, which we found, respectively, to be 4, 230 ± 3, 190 f.-Lm/s (1,320-14,500 
f.-Lm/s) and 1.58±0.05 (1.52- 1.70) for 20 arterioles (39.3±8.7 f.-Lm diameter) and they 
found to be 4, 026±3, 437 f.-Lm/s (1,290- 14,400 f.-Lm/s) and 1.48±0.05 for 12 arterioles 
(25.4 ± 4.2 f.-Lm diameter). Thus, the prevailing flow conditions in both studies were 
remarkably similar as measured by centerline velocity and bluntness of the velocity 
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profile. The slightly higher ratio of Vmax/Vavg that we found is likely due to the larger 
diameters of the arterioles that we considered. As the vessel diameter increases, the 
blunting of the velocity profile decreases (i.e. the Fahneus effect diminishes) and this 
ratio approaches 2, even for blood [28, 51]. 
However, important differences exist between the two studies, which render the 
approach taken by Tangelder et al. unable to accurately resolve the velocity distribu-
tion in the plasma-rich region near the vessel wall, and therefore unable to estimate 
or even detect the endothelial glycocalyx. In particular, Tangelder et al. [44] used 
irregularly shaped fiuorescently labeled platelets (nominally rv 2 f.J,m in diameter) for 
particle tracers in their study, whereas we used regularly shaped rv 0.5-f.J,m-diameter 
fluorescent polystyrene microspheres. Inspection of the viscosity profiles obtained 
(see Figs. 4.4 and 4.5) reveal that the plasma-rich region typically extends rv 3-5 f.J,m 
from the vessel wall (of which rv 0.5 f.J,m is occupied by the glycocalyx). Given the 
large variation in velocity that occurs over the length scale of a platelet within this 
plasma-rich zone, these particle tracers are ultimately too large to provide sufficient 
spatial resolution necessary to accurately extract the velocity and shear rate profiles 
near the vessel wall. Consequently, evidence requiring the existence of a highly non-
linear velocity profile through the glycocalyx in order to satisfy the no-slip condition 
on the endothelial-cell surface was not apparent from the data of Tangelder et al. [44]. 
On the other hand, for the range of vessel diameters that they considered, platelets 
are sufficiently small to provide the resolution necessary to accurately estimate the 
centerline velocity. In addition, since the average velocity is obtained from integra-
tion of the estimated velocity profile, errors in their profiles near the vessel wall were 
diminished when these distributions were integrated to compute Vavg· Thus, it is 
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not surprising that Vmax and Vmax/Vavg reported above for the present study and for 
Tangelder et al. were in good agreement despite the inherent differences in these two 
approaches. 
The present study provides the first direct in vivo demonstration of a hydrody-
namically relevant endothelial glycocalyx in arterioles and a vanishingly small fluid 
shear stress on arteriolar endothelium throughout the cardiac cycle, which, until now, 
has only been established for steady flow in venules. This fundamental result impacts 
our understanding of the biophysics of signal-transduction and biomolecular-transport 
processes that might be preferential to arterioles and is a prerequisite to studies that 
have speculated on the existence of a hydrodynamically relevant glycocalyx in arte-
rioles based on extrapolation from previous results in venules . Similar experimental 
methods to those employed here, using microviscometric analysis in the unsteady 
flow regimes of arterioles, can now be applied to functionally interrogate the endothe-
lial glycocalyx in future studies involving microvascular permeability, endothelial-cell 
mechanotransduction, and vascular disease states associated with inflammation and 
atherosclerosis. 
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Chapter 5 
The Glycocalyx in Syndecan-1 Deficient Mice 
5.1 Introduction 
Much recent research has focused on the structure, composition, function, and clin-
ical significance of the endothelial glycocalyx. It has been implicated in numerous 
physiological functions, including permeability, mechanotransduction, and inflamma-
tion. There is also evidence that the glycocalyx plays a significant role in various 
pathologies, such as atherosclerosis , vascular disease associated with diabetes, and 
ischemia-reperfusion injury. A wide variety of methods, in vivo, ex vivo, and in vitro, 
have been employed to investigate the structure, composition, and function of the 
glycocalyx, but much remains unknown. 
The basic structure that has been proposed for the glycocalyx by Pries et al. [ 6] 
consists of a thin ( < 100 nm) layer of membrane-bound heparan-sulfate proteoglycans 
(HSPGs), glycosaminoglycans (GAGs), and glycoproteins on the vascular endothe-
lium. The remainder of the glycocalyx, which is rv 400 - 500 nm in thickness, is 
made up of molecules adsorbed from the plasma; this portion of the layer is thought 
to be in dynamic equilibrium with t he flowing plasma [6]. Of the molecules found 
at the endothelial cell (EC) surface, HSPGs are thought to be the key components 
that anchor the glycocalyx to the cell [6, 7]. HSPGs consist of a core protein with 
covalently attached GAG side-chains; those found on the apical surface of ECs are 
syndecans-1 , -2, and 4, and glypican-1 [19] . The extent to which any or all of these 
proteins might serve to anchor the glycocalyx to the endothelium has not yet been 
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determined. 
A variety of methods have been employed to investigate the glycocalyx, each of 
which has certain advantages and limitations. The first visualization of the glycocalyx 
was accomplished ex vivo, using electron microscopy (EM) [24]. EM can provide 
information on glycocalyx charge, composition, and structure, but results vary greatly, 
according to the fixation and staining methods employed. The main drawback of EM 
is the potential for damage to the glycocalyx structure during fixation and staining, by 
washing away the adsorbed plasma components or removing of the GAG side-chains 
from HSPGs [6, 7]. There is also the possibility that much of what is seen is actually 
a dehydration artifact or a crystallization artifact resulting from the aqueous fixation 
techniques used [7]. Until recently, EM images of the glycocalyx generally showed a 
layer < 0.1 1-lm in thickness, much thinner than the 0.5 f.-Lm layer observed in vivo. 
Perfusion fixation protocols that do not include post-fixation alcohol dehydration of 
the sample are apparently able to preserve a larger portion of the glycocalyx [10, 26], 
although the presence of fixation artifacts can not be entirely ruled out. Van den 
Berg et al. observed a rv0.2-0.5 f.-Lm glycocalyx in segments of capillaries from rat 
hearts that were perfusion fixed and stained with Alcian blue [10]. Rehm et al. and 
Jacob et al. found a rv0.3 f.-Lm glycocalyx in capillaries of guinea pig hearts that were 
perfusion fixed and stained with Lanthanum [26, 50]. 
Two methods have been developed to visualize the glycocalyx in vivo. The first 
was the dye-exclusion method developed by Vink and Duling [1]. This method, which 
can be applied in microvessels up to rv 15 f.-Lm in diameter [9], was the first to show 
the full extent of the glycocalyx in vivo, revealing a rv 0.5 f.-Lm layer in capillaries. The 
M-PIV method was later developed by Damiano and coworkers and has been used in 
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vivo to interrogate the endothelial glycocalyx in venules and arterioles rv20-70 ~-tm in 
diameter [3-5, 42]. It has also been employed in vitro in the study of ECs cultured in 
cylindrical collagen micro-channels [14, 15]. This method uses intravital microscopy, 
combined with a detailed hemodynamic analysis, to estimate the hydrodynamically 
relevant thickness of the endothelial glycocalyx [3-5]. 
Many studies have attempted to elucidate the structure and composition of the 
glycocalyx using in vitro cell-culture models [14]. While cultured ECs do produce 
what are thought to be glycocalyx components [6, 19], it has also been shown that ECs 
in vitro, when cultured under standard conditions, do not possess a glycocalyx that is 
functionally equivalent to that found in vivo [14, 50, 52] . Using EM and the perfusion 
fixation protocol described in Rehm et al. [26], Chappell et al. [52] reported only a 
rv 0.03 ~-tm glycocalyx on cultured human umbilical vein ECs (HUVECs), compared 
with a rv 0.9 ~-tm glycocalyx in ex vivo sections of human umbilical veins. Potter 
and Damiano used ~-t-PIV to examine HUVECs cultured in collagen microchannels 
and also reported a mean glycocalyx thickness of rv 0.03, compared with a rv 0.5 
~-tm thick glycocalyx found in vivo in mouse cremaster-muscle venules[14]. Until a 
cell-culture model is developed in which ECs in vitro are demonstrated to possess a 
physiologically equivalent glycocalyx, the utility of these methods in investigating the 
structure, composition, and function of the glycocalyx is limited. 
In order to gain insight into the biochemical composition and structure of the 
endothelial glycocalyx, we propose using the established in vivo methods to interro-
gate the glycocalyx in animals deficient in one or more macromolecules thought to 
comprise the glycocalyx. Specifically, to test whether syndecan-1, in particular, is 
an essential anchoring protein for the endothelial glycocalyx, experiments were per-
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formed to estimate the hydrodynamically relevant glycocalyx thickness in syndecan-1 
deficient (Sdcl-/-) mice, as compared with wild-type (WT) mice, before and after 
treatment with hyaluronidase to degrade the glycocalyx. 
5.2 Methods and Materials 
Intravital microscopy, ,u-PIV, and microviscometric analysis were performed as de-
scribed in Chapter 3. Experiments were performed in WT and Sdc1-/- male mice 
that were at least 8 weeks old and weighed 20-30 grams. WT C57bl/6 mice were 
obtained from Charles River labs (Wilmington, MA) or Jackson Labs (Bar Harbor, 
ME). Microviscometric analysis was performed with Mathematica version 8. 
Sdcl-/- Mice 
Sdc1-/- mice bred on the C57Bl/6 background were provided by Dr. PW Park (Chil-
dren's Hospital, Boston, MA). Generation of these mice has been described by Alexan-
der et al. [53] and Park et al. [54]. A sequence of DNA containing a mutation at the 
syndecan-1 locus was incorporated into embryonic stem cells; cells carrying the mu-
tation were then injected into blastocysts [53]. Chimaeric mice were then bred with 
C57BL/6 mates until the null mutation was homozygous [53, 54]. Under normal 
laboratory conditions, Sdcl-/- mice develop normally and are fertile [53- 55]. They 
exhibit no decrease in viability and t here are no apparent differences in routine serum 
chemistry, hematology, or tissue histology as compared with WT mice [55] . 
Quantification of Leukocyte Adhesion 
While collecting ,u-PIV data, there appeared to be a greater number of adherent 
leukocytes in Sdc1-/- mice than in WT mice. To quantify this difference, we counted 
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the number of adherent leukocytes present in the mid-sagittal plane at the beginning 
of data collection for each vessel studied. A leukocyte was counted to be adherent if 
it remained firmly attached to the vessel wall, without rolling, for at least 1 minute 
after the start of data collection. 
5.3 Results 
Estimated G lycocalyx Thickness 
To investigate whether mice lacking syndecan-1 possess a hydrodynamically relevant 
glycocalyx, we collected and analyzed f.L-PIV data in cremaster muscle venules of Sdcl-
/- mice and compared this to data from WT mice. Data was collected before and after 
treatment with hyaluronidase, an enzyme that is known to degrade the glycocalyx 
[9, 14]. Microviscometric analysis was applied to each monotonically filtered subset of 
data to determine the velocity profile and corresponding estimated hydrodynamically 
relevant glycocalyx thickness that resulted in the lowest least squares error in the 
fit to the data [4, 5]. This velocity profile was then used to calculate hemodynamic 
parameters, including the viscosity, shear-stress, and shear-rate distributions. 
Representative results from venules of Sdcl-/- mice, before and after hyaluronidase 
treatment, are shown in Fig. 5.1. The monotonically filtered data and corresponding 
best-fit velocity profile are plotted, along with the resulting viscosity and shear-rate 
distributions. Also shown is the variation in the normalized least-squares error, E*, 
associated with the fit to the f.L-PIV data plotted as a function of the trial glycocalyx 
thickness. The estimate,d glycocalyx thickness, R - a, corresponds to the trial glyco-
calyx thickness associated with the minimum in this curve. The estimated glycocalyx 
thickness is 0.42 f.Lm in the venule not treated with hyaluronidase, whereas there is 
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Figure 5.1: Representative results of ,u-PIV and microviscometric analysis in venules of 
Sdcl-/- mice in vivo. Shown in the left column are results from a 25.1-,um-diameter venule 
before hyaluronidase treatment. In the right column are results from a 48.2-,um-diameter 
venule after hyaluronidase treatment to degrade the glycocalyx. Panels A and B show 
the monotonically filtered ,u-PIV data (circles) and the fitted axisymmetric velocity profile 
(curve) corresponding to trial glycocalyx thickness that produced the smallest least-squares 
error of all admissible trial thicknesses. The shaded region near the vessel wall represents the 
glycocalyx. The corresponding relative blood viscosity (solid curve) and shear-rate (dashed 
curve) distributions are shown in panels C and D. Panels E and F show the variation in 
the normalized least-squares error associated with the fit to the tL-PIV data. The estimated 
glycocalyx thickness is 0.42 f.Lm in the untreated venule and 0.0 1-Lm in the hyaluronidase-
treated venule. 
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Figure 5.2: Representative results of p,-PIV and microviscometric analysis in venules of 
WT mice in vivo, with the same interpretation as Fig. 5.1. Shown in the left column are 
results from a 43.7-p,m-diameter venule before hyaluronidase treatment. In the right column 
are results from a 55.3-p,m-diameter venule after hyaluronidase treatment to degrade the 
glycocalyx. The estimated hydrodynamically relevant glycocalyx thickness is 0.50 p,m in 
the untreated venule and 0.02 p,m in the hyaluronidase-treated venule. 
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Figure 5.3: Mean estimated glycocalyx thickness in venules of Sdc1-/- and WT mice before 
and after hyaluronidase treatment . T he bars show the mean and standard deviation for each 
group. The open circles indicate the estimated glycocalyx thickness for each individual 
vessel in the data set. In t he untreated Sdc1-/ - group, the mean glycocalyx thickness 
was found to be 0.45 ± 0.10 J-Lm (n = 15 venules, N = 6 mice). This is rv 15% thinner 
than the 0.54 ± 0.12 J.-Lm glycocalyx found in WT mice (n = 11, N = 7, p = 0.03). After 
hyaluronidase treatment, the mean glycocalyx thickness was 0.03 ± 0.03 J-Lm in Sdc1-/ - mice 
(n = 7, N = 3,p < 0.001 vs. Sdcl-/ - or WT mice before treatment) and 0.03 ± 0.04 J-Lm in 
WT mice (n = 6, N = 3, p < 0.001 vs. Sdcl-/ - or WT mice before treatment). 
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Table 5.1: Mean physical and hemodynamic parameters in Sdcl-/- and WT mice. Data 
are presented as mean± one SD, for Sdcl-/- and WT mice before and after hyaluronidase 
treatment. Tabulated are the vessel radius, R; estimated glycocalyx thickness, R- a; flow 
rate, Q; ratio of maximum to average flow velocity, Vmax/Vavgi and shear-rate, li'(a) I, and 
shear stress, T(a), magnitude at the blood-glycocalyx interface. 
WT Sdc1-/-
before after before after 
R (J-Lm) 20.2 ± 7.4 19.3 ± 7.4 16.6 ± 4.1 16.4 ± 4.3 
R- a (J-Lm) 0.54 ± 0.12 0.03 ± 0.04 0.45 ± 0.10 0.03 ± 0.03 
Q (106 J-Lm/s) 2.22 ± 2.08 2.40 ± 2.93 1.96 ± 2.05 1.00 ± 1.04 
Vmax/Vavg (J-Lm/s) 1.65 ± 0.07 1.55 ± 0.07 1.69 ± 0.12 1.60 ± 0.04 
b(a)l 1.64 ± 1.63 1.25 ± 0.73 1.44 ± 1.15 0.54 ± 0.20 
T(a) (dyn/cm2 ) 20.8 ± 20.7 15.3 ± 8.9 18.2 ± 14.5 6.6 ± 2.4 
no detectable hydrodynamically relevant glycocalyx remaining in the hyaluronidase-
treated venule. Representative results from WT mice are shown in Fig. 5.2. For the 
WT venules shown the hydrodynamically relevant glycocalyx thickness was found to 
be 0.50 J-Lm in the control venule and 0.02 J-Lm in the hyaluronidase treated venule. 
Microviscometric analysis of J-L-PIV data collected from 15 venules in 6 Sdcl- / -
mice revealed the existence of a hydrodynamically relevant glycocalyx with a mean 
thickness of 0.45 ± 0.10 J-Lm(0.28- 0.69 J-Lm). This is rv 15% thinner than the mean 
glycocalyx thickness of 0.54 ± 0.12 J-Lm (0.37-0.78 J-Lm) found in 11 venules of 7 WT 
mice (p = 0.03). The mean glycocalyx thickness after hyaluronidase treatment was 
found to be 0.03±0.03 J-Lm (0.00- 0.07 J-Lm) in 7 venules of 3 Sdcl-/- mice and 0.03±0.04 
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p,m (0.00-0.11 p,m) in 6 venules from 3 WT mice. These results are summarized in 
Fig. 5.3. Mean vessel radius, glycocalyx t hickness, and hemodynamic parameters for 
each group are summarized in Tab. 5.1. 
Leukocyte Adhesion 
To assess whether the slightly thinner glycocalyx found in Sdc1-/ - mice might be 
functionally different from that found in WT mice, we compared the number of ad-
herent leukocytes observed in vessel segments from each group. The mean number 
of adherent leukocytes in WT mice was 0.8 ± 1.0 (n = 24, N = 6) , compared with 
1.5 ± 1.1 (n = 25, N = 13,p = 0.02) found in Sdc1-/ - mice. On average, data was 
collect ed from a greater number of venules per mouse in Sdc1-/ - mice than in WT 
mice. Since the cremaster preparation t ends to become more inflamed with increasing 
duration of the experiment, vessels observed later in the experiment would tend to 
exhibit more leukocyte adhesion. To account for this, we also analyzed a limited data 
set consisting of only the first 1- 2 venules observed in each mouse (note that in some 
animals data was only collected from one venule before enzyme treatment). With this 
restricted data set, our findings of increased leukocyte adhesion in Sdc1-/ - mice per-
sisted. In the restricted data set the mean number of adherent leukocytes in WT mice 
was 0.7 ± 0.8 (n = 18, N = 13) , compared with 1.5 ± 1.3 (n = 12, N = 6,p = 0.04) 
found in Sdc1-/ - mice. Fig. 5.4 shows the number of adherent leukocytes vs. the 
percentage of vessels studied in Sdcl-/ - and WT mice, for the restricted data set . In 
WT mice, only 11% of vessels studied had 2 or more adherent leukocytes, whereas in 
Sdcl-/ - mice this increased to 42%. 
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Figure 5.4: Leukocyte Adhesion in Sdcl-/- and WT mice. This chart shows the percentage 
of vessel segments in each group having 0, 1, 2, 3 or 4 adherent leukocytes. None of the 
vessels observed had greater than 4 adherent leukocytes visible in the mid-sagittal plane. 
In Sdc1-/- mice, 42% of vessels studied had 2 or more adherent leukocytes, whereas in WT 
mice this number dropped to 11%. The mean number of adherent leukocytes was 1.5 ± 1.3 
(n = 12) in Sdc1-/- mice and 0.7 ± 0.8 (n = 18;p = 0.04) in WT mice. 
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5.4 Discussion 
These results provide the first in vivo evidence that syndecan-1 is not an essential 
component of the endothelial glycocalyx. Despite the complete absence of syndecan-1, 
healthy Sdcl-/ - mice are able to synthesize and maintain a hydrodynamically relevant 
glycocalyx. The glycocalyx found in Sdc1-/- mice appears to be "' 0.1 p,m thinner, 
on average, than that of WT mice, and this may be due to absence of syndecan-
1. As in WT mice, the glycocalyx in Sdcl-/- mice was almost completely degraded 
after enzymatic treatment with hyaluronidase. The error associated with using p,-PIV 
and microviscometric analysis to estimate glycocalyx thickness has previously been 
estimated to be < 0.05 p,m [42]. Therefore, a difference in glycocalyx thickness of 0.1 
p,m is large enough to be detectable by this method. Additionally, an approximately 
two-fold increase in leukocyte adhesion was observed in Sdcl-/- mice relative to WT 
mice. These differences suggest that the glycocalyx found in Sdc1-/- mice may be 
structurally and functionally different from that found in WT mice. 
Syndecan-1 has been linked to a wide variety of physiological processes and is 
expressed in many tissues, including the vascular endothelium, during growth and 
development [56]. However, mice lacking syndecan-1 develop normally and are fertile 
[53, 54] . Under normal laboratory conditions they exhibit no decrease in viability and 
there are no apparent differences in routine serum chemistry, hematology, or tissue 
histology as compared with WT mice [55] . In this context , it is unsurprising that Sdcl-
/- mice are able to synthesize and maintain a hydrodynamically relevant endothelial 
glycocalyx. Even in some tissues that normally have high levels of syndecan-1 ex-
pression, no defects have been observed in these mice [53]. Therefore, these results 
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do not indicate that syndecan-1 is not a component ofthe glycocalyx in animals with 
normal syndecan-1 expression, only that it is not a prerequisite for the existence of a 
hydrodynamically relevant endothelial glycocalyx. 
There is evidence that only a subset of HS signaling pathways are affected in 
Sdc1-/- mice, while others, including those required for normal development, are not 
[53]. Additionally, there appears to be no difference in HS structure in Sdcl-/- mice, 
even in tissues with high syndecan-1 expression [57]. It has also been shown that the 
structure of HS chains is independent of the core protein, with HS chains on syndecan-
1 and syndecan-4 being indistinguishable from each other [58]. Thus, HS structures 
normally associated with syndecan-1 could bind to other core proteins instead, and 
any HS function that is independent of core protein structure could still occur [57, 58]. 
It could be that syndecan-1 is a major component of, or even an anchoring protein 
for, the glycocalyx in WT mice, but that in the absence of syndecan-1, ot her HSPGs 
are able to fill that role. 
When challenged, as in cases of injuries or disease, Sdcl-/- mice exhibit a variety 
of phenotypes. It has been reported that they exhibit impaired wound healing and 
increased mortality, accompanied by defects in cell proliferation, and prolonged in-
flammation [55, 59]. Similar observations have been made in Sdcl-/- mice exposed to 
certain toxins or diseases. Under such exposure, the animals experienced increased 
organ damage and mortality, which was accompanied by persistent systemic inflam-
mation and exaggerated neutrophillic inflammation, relative to WT mice [60, 61]. In 
each of these studies, upregulation and/ or dysregulation of certain cytokines, inte-
grins, and adhesion molecules were also present [55, 59-61]. In addition, while Sdcl-/-
mice may exhibit a slight increase in leukocyte-endothelial interactions and adhesion 
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under normal conditions, this difference is much more dramatic under inflammatory 
conditions, with 100-fold greater leukocyte adhesion occurring in Sdc1-/- vs. WT 
mice after treatment with TNF-a [62, 63]. Taken together, these results demonstrate 
that syndecan-1 plays a critical role in inflammation, particularly in the resolution of 
inflammation, through the regulation of integrins, cytokines, and adhesion molecules 
and through the modulation of leukocyte activity and adhesion. 
The slightly thinner glycocalyx and increased leukocyte adhesion observed in Sdcl-
/ - mice in the present study could be the result of mild inflammation that inevitably 
accompanies surgical preparation of the cremaster muscle. While much care is taken 
in handling the tissue, and a P-selectin antibody is used to minimize leukocyte rolling, 
the method is inherently invasive and mild inflammation is unavoidable. It has been 
established that the glycocalyx acts as a barrier to leukocyte adhesion and glycocalyx 
shedding is a normal part of the inflammatory response [12]. Given the evidence of a 
dysregulated inflammatory response in Sdcl-/- mice, it could be expected that even 
under mild inflammatory conditions, leukocyte adhesion and glycocalyx shedding 
would be greater than what is observed in WT mice. Thus, it is possible that under 
entirely non-inflammatory conditions, the glycocalyx in Sdcl-/- mice is comparable 
in thickness to that found in WT mice. Whether or not the observed differences 
are the result of mild inflammation, they are suggestive of structural and functional 
differences between the glycocalyx in WT and Sdcl-/- mice. It has been proposed that 
one way in which the glycocalyx modulates leukocyte-EC interactions is by acting as 
a physical barrier to leukocyte attachment, and that primary capture occurs when 
the glycocalyx is crushed by leukocytes as they exit capillaries and enter inflamed 
post-capillary venules [3, 7]. Therefore, a reduction in glycocalyx thickness alone 
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could facilitate leukocyte attachment. 
This is the first investigation to assess the status of the endothelial glycocalyx in 
vivo in animals lacking what has been speculated to be a primary component of the 
glycocalyx. These results show that syndecan-1 is not an essential component of the 
glycocalyx, as Sdcl-/- mice are able to synthesize and maintain a hydrodynamically 
relevant layer; however, there is evidence that the glycocalyx observed in these mice 
differs from what exists in WT mice. Now that the existence of a glycocalyx in Sdcl-/-
mice has been established, investigations into the differences between this glycocalyx 
and that found in WT mice could be used to explore the role of syndecan-1 as a 
component of the endothelial glycocalyx and to elucidate mechanisms of glycocalyx 
function under inflammation. 
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Chapter 6 
The Effects of Hyperglycemia on the Glycocalyx 
6.1 Introduction 
Nearly all long-term complications of diabetes have their origins in vascular disease 
arising from chronic hyperglycemia. It has been shown in both type 1 and type 2 
diabetes that a reduction in chronic hyperglycemia is accompanied by a decrease in 
the risk of long-term complications, and that a greater reduction provides a greater 
benefit [64, 65]. The etiology of this vascular disease has been strongly linked to 
hyperglycemia-induced overproduction of superoxide by the mitochondrial electron-
transport chain and resulting endothelial cell (EC) dysfunction [20, 66]. In addi-
tion, free fatty acid metabolism in type 2 diabetes and insulin resistance syndrome 
also contribute to oxidative stress [21]. Efforts to mitigate the deleterious effects of 
hyperglycemia-induced reactive oxygen species (ROS) through the use of exogenous 
free-radical scavengers have been attempted in cell culture [66, 67], in animal models 
[67, 68], and in human clinical trials [69-71]. A necessary criterion for the success of 
any therapeutic designed to scavenge excess ROS is that such an intervention must 
maintain the functional integrity of the glycocalyx on the luminal surface of vascular 
endothelium. 
The EC surface glycocalyx represents the first line of defense for the endothelium 
against vascular damage. This rv 0.5 J-lm layer on the luminal surface of the vascular 
endothelium has been demonstrated to selectively exclude macromolecules and retard 
plasma flow in capillaries, venules, and arterioles in vivo [1, 3, 4, 14, 42]. There is sub-
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stantial evidence that the glycocalyx plays an important role in many physiological 
functions, such as inflammation, permeability, mechanotransduction, and hemostasis 
[6, 7] . Membrane-bound molecules found on the luminal surface of ECs include glyco-
proteins , heparan sulfate proteoglycans (HSPGs), and glycoscaminoglycans (GAGs) 
[6]. In addition to membrane-bound components, proteins and other molecules ad-
sorbed from the plasma are considered to be a major component of the glycocalyx; 
these components are thought to be in a dynamic equilibrium between the glycocalyx 
and flowing blood [6]. Under normal conditions, the ECs are thought to actively reg-
ulate the glycocalyx composition in response to changes in their microenvironment 
by adjusting the rate of synthesis and secretion of the various glycocalyx components 
[7]. 
It has been established in vivo that prolonged exposure of circulating fluorescent 
plasma tracers to epi-fluorescent illumination (light-dye treatment) results in partial 
degradation of the glycocalyx in the microcirculation [1 , 3, 4] and that this effect is 
abolished in the presence of exogenous superoxide dismutase/ catalase (SOD/ CAT) 
[1]. It has also been shown that the glycocalyx is degraded in the presence of oxidized 
low-density lipoproteins [72] . These results suggest that hyperphysiological levels of 
ROS can overwhelm the ability of endothelial cells (ECs) to maintain the glycocalyx, 
in which case the layer is shed faster than it can be replaced. Thus, the status 
of the glycocalyx can be viewed as a native physiological metric for how effectively 
the microcirculation is clearing ROS as they are being generated. In the case of 
hyperglycemia-induced overproduction of superoxide, it is of general interest to know 
whether acute and chronic hyperglycemia result in degradation of the glycocalyx, and 
if treatments aimed at reducing levels of ROS could provide a practical augmentation 
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to the native ability of the glycocalyx to scavenge blood-borne free radicals. 
Several major pathways of diabetic complications can be traced to overproduc-
tion of superoxide by the mitochondrial electron transport chain [20, 66, 73, 74]. This 
overproduction of superoxide activates protein kinase C and nuclear factor-K:B, lead-
ing to the formation of the strong oxidant peroxynitrite and resulting in endothelial 
dysfunction and proinflammatory conditions [20, 74]. One mechanism of glycocalyx 
degradation resulting from hyperglycemia could be superoxide migrating out of ECs, 
where they could then degrade the glycocalyx directly. This would be a similar mech-
anism to the degradation that is thought to occur during light-dye treatment. The 
major difference would be that during light-dye treatment the oxidants are generated 
in the circulation, while in hyperglycemia they are generated within the EC. In ad-
dition, EC dysfunction resulting from hyperglycemia might also reduce or possibly 
even abolish the ability of ECs to maintain the glycocalyx. This suggests two possi-
ble approaches to protecting the glycocalyx from damage induced by hyperglycemia: 
scavenging excess ROS after they have formed or preventing excess ROS formation 
and subsequent EC dysfunction. 
Previous studies attempting to examine the effects of hyperglycemia on the glyco-
calyx in vivo have used indicator-dilution, which is an indirect method that estimates 
systemic glycocalyx volume [43, 75] . It was reported that a six-hour hyperglycemic 
clamp resulted in a 50% reduction in systemic glycocalyx volume [75]. A similar 
reduction in glycocalyx volume was also reported in people with type 1 diabetes [43]. 
While this may provide some evidence of glycocalyx damage resulting from hyper-
glycemia, a critical review of the indicator-dilution method concluded that, due to 
several substantial sources of error , it could not be considered a reliable measure 
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glycocalyx volume [76]. In addition, while this method has the advantage of being 
non-invasive and can be used in humans, it does not give any specific information 
about the glycocalyx thickness or the surrounding hemodynamic environment. Using 
the ,u-PIV method, it is possible to estimate the hydrodynamically relevant glycoca-
lyx thickness in individual microvessels, allowing for direct investigation of the effects 
of acute and chronic hyperglycemia on the glycocalyx in vivo. 
In order to establish the effects of acute and chronic hyperglycemia on the mi-
crovascular glycocalyx in vivo, ,u-PIV and microviscometric analysis were applied in 
venules rv 20-70 ,urn in diameter in the cremaster muscle of healthy wild-type (WT) 
and non-obese diabetic (NOD) mice, acutely hyperglycemic WT and NOD mice, and 
chronically hyperglycemic NOD mice. Chronic hyperglycemia resulted in glycoca-
lyx degradation similar to that previously observed after light-dye treatment. In 
an attempt to protect the glycocalyx and, by extension, the vasculature from this 
degradation, mice were given treat ment with synthetic SOD/CAT mimetics or the 
mitochondrial uncoupler 2,4 dinitrophenol (DNP). 
6.2 Methods and Materials 
Intravital microscopy, ,u-PIV, and microviscometric analysis were performed as de-
scribed in Chapter 2: General Methods. Microviscometric analysis was performed 
with Mathematica version 8. Experiments were performed in male mice that were at 
least 8 weeks old. WT C57bl/6 mice were obtained from Charles River labs (Wilm-
ington, MA) or Jackson Labs (Bar Harbor, ME). 
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Experimental Groups 
Experiments were performed in healthy (normoglycemic) WT and NOD mice, acutely 
hyperglycemic WT and NOD mice, and chronically hyperglycemic NOD mice. In 
chronically hyperglycemic mice, there were five experimental groups. One group 
received no treatment, while the remaining groups all received treatment with subsis-
tence-level insulin therapy. Additionally, three groups received treatment with either 
a synthetic SOD/CAT mimetic (EUK-189 or EUK-207) or the mitochondrial uncou-
pler DNP. Further details regarding each experimental group are given below. 
Mouse Model of Acute Hyperglycemia 
An infusion pump (MiniMed 508, Medtronic Diabetes, Northridge, CA) connected 
to the carotid cannula was used for continuous administration of a glucose solution. 
An initial bolus containing "' 50 mg glucose was given, followed by a continuous 
infusion at a rate of 20- 30 mg/hr. Blood glucose (BG) levels were sampled every 15-
20 minutes (OneTouch Ultra, LifeScan, Inc. , Milpitas, CA) and reached or exceeded 
400 mg/ dL in "' 30 minutes. The infusion rate was adjusted as needed to maintain 
BG levels above this level for the duration of the experiment. Collection of 11-PIV 
data began "' 1.5 hours after the glucose infusion began and continued for up to 2 
hours thereafter. Experiments were performed in healthy WT and NOD mice. 
Mouse Model of Chronic Hyperglycemia 
NOD/LtJ and NOD.scid mice were obtained from J ackson Labs. Approximately 50% 
of male and 80% of female NOD /LtJ mice spontaneously develop diabetes between 
15 and 30 weeks of age [77] . NOD.scid mice are a control strain for NOD/LtJ and 
do not spontaneously develop diabetes. Diabetes was induced in NOD.scid mice 
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with an intraperitoneal injection of a cell suspension created from the spleen of dia-
betic NOD/LtJ mice [78]. A diabetic NOD/LtJ mouse was sacrificed, the spleen was 
removed, and the spleen cells were suspended in rv 1 ml sterile saline. An int raperi-
toneal injection of this suspension was then administered into NOD.scid mice. Each 
NOD/LtJ spleen provided enough cells to induce hyperglycemia in 4-5 NOD.scid 
mice. All NOD.scid mice developed diabetes within 3-7 weeks post-injection. BG 
levels were checked (OneTouch Ultra, LifeScan, Inc.) in each mouse via a tail-vein 
blood sample 1- 2 times per week unt il the onset of diabetes and 2- 3 times per week 
thereafter. Mice were determined to have fully developed diabetes when BG levels 
consistently exceeded 400 mg/ dl. 
Treat ment with Subsistence-level Insulin 
For the purposes of this study, a subsistence-level dose of insulin was defined as an 
amount sufficient to maintain the pre-diabetic weight of the mice without normalizing 
glycemic levels. Subsistence-level insulin treatment was administered using Linbit 
implants (Linshin Canada, Inc., Toronto, Ontario, Canada). The implants are made 
from a compressed mixture of insulin and micro-recrystallized palmitic acid [79]. 
When implanted subcutaneously, the release rate is rv 0.1 units/day/implant for at 
least 30 days. Continuous release of insulin results in a more stable BG level than is 
normally achieved with insulin injections [80]. 
Mice were anesthetized with isofl.uorane, following the procedure described in 
Chapter 3. A trocar was used to insert 2-3 implants subcutaneously under the 
mid-dorsal skin, following t he manufacturer's instructions. The required dosage was 
estimated based on the weight of the animal; as the desired result was only to pro-
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vide subsistence-level insulin therapy, and not to reduce the BG to normoglycemic 
levels, the dosage used was less than that recommended by the manufacturer. After 
recovery from anesthesia, mice were returned to clean cages and observed regularly 
for any sign of pain or infection. This procedure was completed in rv 10 minutes. 
Treatment with EUK-189 or EUK-207 
The synthetic SOD/CAT mimetic compounds EUK-189 and EUK-207 [81] were pro-
vided by Susan Doctrow (Boston University, Boston, MA). The chemical structure 
of these compounds is shown in Fig. 6.1. These compounds are derived from a 
class of salen-manganese complexes that have been shown to exhibit both SOD and 
CAT activities, neutralizing both ROS superoxide and hydrogen peroxide [81, 82] . 
Treatment with SOD/CAT mimetics of t his type has been shown to have a protec-
t ive effect in multiple animal models of diseases with an oxidative stress component 
[83]. In mouse models, EUK-189 and EUK-207 have been demonstrated to protect 
against age-related cognit ive deficits [81] and radiation-induced EC apoptosis [84] . 
The SOD/CAT activities of the two compounds are similar [83], but EUK-207 is 
more biologically stable and has a longer plasma half-life [81]. 
Treatment with EUK-189 or EUK-207 was administered via subcutaneously im-
planted osmotic pumps (Alzet model 1002, Durect Corp., Cupertino, CA). Treatment 
began one week after onset of chronic hyperglycemia and the beginning of subsistence-
level insulin therapy. Each pump was filled with 6 mg/ml EUK-189 or EUK-207 
dissolved in water (concentration: 12.8 mM for EUK-189, 11.4 mM for EUK-207). 
The release rate of these pumps is 0.25 ,ul/hr for 14 days. This resulted in a dosage 
of rv 1. 3 mg/kg/day. This treatment and dosage is similar that used previously is 
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EUK-207 
Figure 6.1: Structures of EUK-189 and EUK-207, synthetic salen-Mn compounds that 
act as SOD/ CAT mimetics, scavenging both superoxide and hydrogen peroxide. Due to 
its cyclic structure, EUK-207 is more biologically stable than EUK-189. Figure reproduced 
from Liu et al. [81], Copyright 2003 National Academy of Sciences, USA. 
mouse models [81, 84]. To implant the pump, mice were anesthetized with isofiuo-
rane, a small incision (""' 1 em) was made, and the pump was inserted under the mid 
dorsal skin, on the opposite side from any insulin implants. The incision was then 
closed with a staple. The animal was injected with buprenorphine (0.1 mg/kg) just 
before and as needed following each procedure for both insulin and osmotic pump 
implantations. This procedure was completed in ""' 15 minutes. After recovery from 
anesthesia, mice were returned to clean cages and observed regularly for any sign of 
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pain or infection. 
Treatment with DNP 
DNP uncouples oxidative phosphorylation in mitochondria by allowing protons to 
pass through the inner mitochondrial membrane independently from ATP synthesis 
[85, 86]. It does this by acting as a protonophore, passing in a protonated state 
through the inner membrane into t he mitochondrial matrix, then losing a proton, 
and passing back to t he intermembrane space as an anion to repeat this cycle [85]. 
This results in increased electron transport and oxygen consumption, reducing mito-
. chondrial superoxide production [86, 87]. 
Treatment with DNP (Sigma-Aldrich Co., St. Louis, MO) was administered to 
the mice orally via the water supply at a concentration of 1 mg/l. This low dosage 
has previously been shown to increase t issue oxygen consumption, reduce ROS levels , 
and increase longevity in healthy mice [88]. The treatment period began one week 
after the onset of chronic hyperglycemia and the beginning of subsistence-level insulin 
therapy and lasted for two weeks. 
Thiobarbituric Acid Reactive Substances (TEARS) Assay 
Malondialdehyde (MDA) is a product of lipid peroxidation and can be used as an 
indicator of oxidative stress. At high temperature and acidic pH, MDA reacts with 
thiobarbituric acid (TBA) to form an MDA-TBA adduct. This adduct can be de-
tected by spectrophotometry or fluorometry. The assay for TBARS is an established 
method for estimating levels of lipid peroxides in tissues, plasma, and urine [89-91]. 
Assays for TBARS were conducted in plasma samples from normoglycemic mice 
and chronically hyperglycemic mice t reated with subsistence-level insulin therapy 
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alone or in combination with either EUK-207 or DNP. Blood was collected from 
animals via cardiac puncture, with heparin added as an anticoagulant . Samples 
were immediately centrifuged at 1000 x g and -4°C for 10 minutes . The plasma 
layer was then pipetted off and stored at -80°C. The TBARS assay was performed 
using a commercially available kit (Cayman Chemical, Ann Arbor, MI) following 
manufacturer's instructions. Presence of the MDA-TBA adduct was detected by 
reading the fluorescence at an excitation wavelength of 530 nm and an emission 
wavelength of 550 nm. 
6.3 Results 
Glycoclayx Thickness in Normoglycemic Mice 
J.L-PIV experiments were performed in venules of normoglycemic WT and NOD mice 
under normoglycemic conditions to establish whether the hydrodynamically relevant 
glycocalyx thickness in NOD mice, prior to the development of hyperglycemia, is 
similar to that found in WT mice. Shown in Fig. 6.2 are the monotonically filtered 
J.L-PIV data sets, the estimated velocity profiles, and the hydrodynamically relevant 
glycocalyx thickness in a normoglycemic WT mouse (A) and NOD mouse (B). The 
mean glycocalyx thickness was found to be 0.50 J.Lm in the venule shown from the WT 
mouse and 0.46 J.Lm in the venule shown from the NOD mouse. In venules of norma-
glycemic NOD mice, the mean glycocalyx thickness was estimated to be 0.46 ± 0.05 
J.Lm (0.42- 0.52 J.Lm, n = 4 venules, N = 2 mice), compared with 0.54 ± 0.12 J.Lm 
in healthy WT mice (0.37-0.78 J.Lm, n = 11, N = 7). As there was no statistically 
significant difference (p = 0.26) in glycocalyx thickness between normoglycemic WT 
and NOD mice, they were combined into one group of normoglycemic mice for fur-
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ther analysis. The mean glycocalyx thickness for the combined group was 0.52 ± 0.11 
j),m (0.37- 0.78 j),m, n = 15, N = 9). After treatment with hyaluronidase, the gly-
cocalyx in normoglycemic WT mice was almost completely degraded, with a mean 
estimated thickness of only 0.03 ± 0.04 j),m (0.0- 0.11 j),m, n = 6, N = 3, p < 0.001 vs. 
untreated). Microviscometric analysis results in a hyaluronidase treated venule are 
shown in Fig. 6.2(C). 
Glycocalyx Thickness in Mice with Acute Hyperglycemia 
Acute hyperglycemia experiments were also performed in both WT and NOD mice; all 
mice were normoglycemic prior to beginning each experiment. Representative results 
of microviscometric analysis in a WT mouse with acute hyperglycemia are shown 
in Fig. 6.3(A) . The estimated glycocalyx thickness in the venule shown is 0.38 j),m. 
After 1.5-3.5 hours of hyperglycemia, the mean hydrodynamically relevant glycocalyx 
thickness was 0.39±0.15 j),m in venules ofWT mice (0.21- 0.62 j.J,m, n = 5, N = 3) and 
0.46±0.24 j),m in NOD mice (0.24- 0.75 j),m, n = 4, N = 1). When results from acutely 
hyperglycemic WT and NOD mice are considered as one group, the mean glycocalyx 
thickness is 0.42 ± 0.19 J.1,m(0.21- 0.75 j),m, n = 9, N = 4). These results were not 
found to be significantly different from those in normoglycemic WT and NOD mice 
(p = 0.11), as shown in Fig. 6.4. It should be noted that the standard deviation in 
the acute hyperglycemia group was much greater than in the normoglycemia group. 
Glycocalyx Thickness in NOD Mice with Chronic Hyperglycemia 
j.J,-PIV experiments were performed in NOD mice after 1- 2 weeks of chronic, untreated 
hyperglycemia. The mean BG level in these mice exceeded 550 mg/ dl. In chronically 
hyperglycemic NOD mice treated with subsistence-level insulin, experiments were 
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Figure 6.2: Representative p,-PIV results from normoglycemic mice, before and after 
hyaluronidase treatment to degrade the glycocalyx. In the left column are the monotoni-
cally filtered p,-PIV data (circles) and the fitted axisymmetric velocity profile (curve) cor-
responding to trial glycocalyx thickness that produced the smallest least-squares error of 
all admissible trial thicknesses. The shaded region near the vessel wall represents the gly-
cocalyx. In the right column is the variation in the normalized least-squares error, E *, 
associated with the fit to the p,-PIV data. Panel A shows results from a 43.8-p,m-diameter 
venule in a normoglycemic WT mouse; the estimated glycocalyx thickness is 0.5 p,m. Panel 
B shows results from a from a 26.4-p,m-diameter venule in a normoglycemic NOD mouse; the 
estimated glycocalyx thickness is 0.46 p,m. Panel C shows results from 26.0-p,m-diameter 
venule in a normoglycemic WT mouse treated with hyaluronidase; the estimated glycocalyx 
thickness is 0.0 p,m. 
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Figure 6.3: Representative M-PIV results from mice with acute or chronic hyperglycemia, 
with the same interpretation as Fig. 6.2. Panel A shows results from a 34.2-f.l,m-diameter 
venule in an acutely hyperglycemic WT mouse; the estimated glycocalyx thickness is 0.38 
f.L,m. Panel B shows results from a from a 32.2-f.l,m-diameter venule in a NOD mouse after 
approximately one week of chronic, untreated hyperglycemia; the estimated glycocalyx 
thickness is 0.09 f.L,m. Panel C shows results from a 46.4-f.l,m-diameter venule in an NOD 
mouse after three weeks of chronic hyperglycemia, treated with a subsistence-level of insulin; 
the estimated glycocalyx thickness is 0.19 f.L,m. 
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Figure 6.4: Mean estimated hydrodynamically relevant glycocalyx thickness, as deter-
mined by microviscometric analysis, in venules of WT and NOD mice. The bars show the 
mean and standard deviation for each group. The open circles indicate the estimated gly-
cocalyx thickness for each individual vessel in the data set. In venules of normoglycemic 
WT and NOD mice, the mean glycocalyx thickness was 0.52 ± 0.11 p,m (n = 15). In WT 
and NOD mice with acute hyperglycemia, the mean glycocalyx thickness was 0.42 ± 0.19 
p,m(n = 9). In normoglycemic WT mice treated with hyaluronidase to degrade the layer, 
the glycocalyx thickness is 0.03 ± 0.04 p,m (n = 6). In NOD mice, after approximately 
one week of untreated chronic hyperglycemia, the glycocalyx thickness is 0.11 ± 0.15 p,m 
( n = 17); this is significantly different from the glycocalyx thickness found in normoglycemic 
and acutely hyperglycemic mice (p < 0.001) and not significantly different from that of the 
hyaluronidase-treated group (p = 0.186). In NOD mice with chronic hyperglycemia, treated 
with subsistence-level insulin, the glycocalyx thickness is 0.22±0.17 p,m (n = 10); this is sig-
nificantly different from that found in normoglycemic (p < 0.001) or acutely hyperglycemic 
(p = 0.03) mice and also significantly different from the glycocalyx of mice treated with 
hyaluronidase (p = 0.02). 
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performed after t hree weeks of treatment. The mean BG in these mice was rv 450 
mg/dl. Shown in Fig. 6.3 are results from a mouse with untreated chronic hyper-
glycemia (B) and a chronically hyperglycemic mouse receiving a subsistence-level of 
insulin (C). The estimated glycocalyx thickness in the untreated mouse is 0.09 11m, 
while the glycocalyx t hickness in t he mouse treated with subsistence-level insulin is 
0.19 J-tm. 
The mean estimated hydrodynamically relevant glycocalyx thickness in mice with 
untreated chronic hyperglycemia was 0.11 ± 0.15 ~-tm (0.0-0.45 J-tm, n = 17). This 
result is significantly less than t hat found in normoglycemic mice (p < 0.001). No 
significant difference was found when compared with mice treated with hyaluronidase 
to degrade t he glycocalyx (p = 0.19). In mice treated with subsistence-level insulin 
therapy, the mean glycocalyx thickness was 0.22 ± 0.17 ~-tm (0.0-0.64 J-tm, n = 10) . 
This was significantly less t han that found in t he normoglycemic group (p < 0.001), 
significantly greater than that found in the hyaluronidase-treated group (p = 0.02), 
and not significantly different from that found in t he untreated-chronic-hyperglycemia 
group (p = 0.09). These results are summarized in Fig. 6.4. 
Glycocalyx Thickness in Mice Treated with SOD/CAT 
~-t-PIV experiments were performed in chronically hyperglycemic NOD mice receiving 
treatment with t he synthetic SOD/CAT mimetics EUK-189 or EUK-207 in combina-
tion with subsistence-level insulin t herapy. The mean BG in the group treated with 
EUK-189 was rv 300 mg/dl, while the mean BG in the group treated wit h EUK-
207 was rv 410 mg/ dl. Microviscometric analysis results from a mouse treated with 
EUK-189 and a mouse treated wit h EUK-207 are shown in Fig. 6.5 (A) and (B) , re-
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spectively. The estimated glycocalyx thickness was found to be 0.30 J-Lm in the venule 
shown from the mouse treated with EUK-189 and 0.40 J-Lm in the venule shown from 
the mouse treated with EUK-207. 
Mice that received treatment with subsistence-level insulin and EUK-189 had a 
mean glycocalyx thickness of 0.31 ± 0.23 J-Lm (0.0- 0.74 J-Lm, n = 10). This result was 
not significantly different from the mean glycocalyx in mice treated with subsistence-
level insulin alone (p = 0.32). However, when compared with either the hyaluronidase-
treated group or the untreated-hyperglycemia group, the difference was found to 
be significant (p = 0.01). This thickness was also significantly less than that of 
normoglycemic mice (p = 0.007). 
In mice treated with EUK-207, the mean estimated glycocalyx thickness was 
0.41 ± 0.14 J-Lm (0.22- 0.67 J-Lm, n = 10). As with the EUK-189 group, this mean 
thickness was found to be significantly greater than that found in both hyaluronidase-
treated mice and in mice with untreated chronic hyperglycemia (p < 0.001). The 
mean glycocalyx thickness in the EUK-207 treatment group was also found to be 
significantly thicker than in the subsistence-level insulin-only group (p = 0.02), but 
significantly thinner than in normoglycemic mice (p = 0.04). However, when the 
mean glycocalyx thicknesses of the EUK-189 and EUK-207 groups were compared 
directly with one another , the difference was not found to be statistically significant 
(p = 0.293). These results are summarized in Fig. 6.6. 
Glycocalyx Thickness in Mice Treated with DNP 
~-t-PIV experiments were performed in chronically hyperglycemic NOD mice receiving 
treatment with DNP in combination with subsistence-level insulin therapy. The mean 
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Fig ure 6 .5 : Representative p,-PIV results in chronically hyperglycemic mice treated with 
SOD /CAT or DNP, in addition to subsistence-level insulin. Same interpretation as Fig. 6.2. 
Panel A shows results from 49.6-p,m-diameter venule in a mouse treated with EUK-189; the 
estimated glycocalyx thickness is 0.30 p,m. Panel B shows results from a from a 27.6-p,m-
diameter venule in a mouse treated with EUK-207; the estimated glycocalyx thickness is 
0.40 p,m. Panel C shows results from a 45.4-p,m-diameter venule in a mouse treated with 
DNP; the estimated glycocalyx thiclmess is 0.44 p,m. 
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Figure 6.6: Mean glycocalyx thickness in chronically hyperglycemic mice treated with 
subsistence-level insulin and SOD /CAT or DNP. The bars show the mean and standard 
deviation for each group. The open circles indicate the estimated glycocalyx thickness 
for each individual vessel in the data set . In venules of normoglycemic WT and NOD 
mice, the mean glycocalyx thickness was 0.52 ± 0.11 J-Lm (n = 15). In NOD mice with 
chronic hyperglycemia, treated with subsistence-level insulin, the glycocalyx thickness is 
0.22 ± 0.17 J-Lm (n = 10) ; this is significantly different from that found in normoglycemic 
mice (p < 0.001) . In mice treated with the synthetic SOD/CAT EUK-189 mimetic in 
combination with subsistence-level insulin, the glycocalyx thickness is 0.31 ± 0.23 J-Lm (n = 
10) ; this significantly different from the normoglycemic group (p = 0.007), but not different 
from the insulin-only group (p = 0.32) . In mice treated with EUK-207 in combination 
with subsistence-level insulin, the glycocalyx thickness is 0.41 ± 0.14 J-Lm (n = 10); this is 
significantly different from both the normoglycemic group (p = 0.04), and the insulin-only 
group (p = 0.02). In mice treated with DNP in combination with subsistence-level insulin, 
the glycocalyx thickness is 0.40 ± 0.08 J-Lm (n = 10); this is significantly different from both 
the normoglycemic group and the insulin-only group (p < 0.01). 
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BG in these mice was rv 400 mg/ dl. Microviscometric analysis results from a mouse 
treated with DNP are shown in Fig. 6.5(C). The estimated glycocalyx thickness in 
the venule shown is 0.44 J-lm. 
The mean estimated glycocalyx thickness in chronically hyperglycemic mice treat-
ed with DNP in combination with subsistence-level insulin therapy was 0.40 ± 0.09 
J-lm (0.29-0.54 J-lm, n = 10). This thickness was significantly greater than that found 
in both hyaluronidase-treated mice and in mice with untreated chronic hyperglycemia 
(p < 0.001) . It was also significantly thicker than that found in the subsistence-level 
insulin-only group (p = 0.02). However, as with the SOD/CAT treatment groups, the 
mean glycocalyx thickness in the DNP treatment group was still significantly less than 
in normoglycemic mice (p = 0.006). These results are summarized in Fig. 6.6(C). 
Oxidative Stress Levels 
To assess levels of oxidative stress, an assay was used to measure plasma TBARS in 
normoglycemic and chronically hyperglycemic mice. In normoglycemic NOD mice, 
plasma TBARS was 2.91 ± 0.62 fJ,M (n = 4). Elevated TBARS levels were found in 
NOD mice with chronic hyperglycemia treated with subsistence-level insulin; plasma 
TBARS was 4.31±0.25 fJ,M (n = 4,p = 0.006 vs. normoglycemic). Mice treated with 
EUK-207 or DNP in addition to subsistence-level insulin had TBARS levels between 
those of normoglycemic mice and the hyperglycemic mice treated only with insulin. 
In mice treated with EUK-207 in addition to subsistence-level insulin, plasma TBARS 
was 3.40±0.74 fJ,M (n = 3). In mice treated with DNP in addition to subsistence-level 
insulin, plasma TBARS was 3.72 ± 0.24 fJ,M (n = 3). These results are summarized 
in Fig. 6. 7. Due to the small sample size, these results are preliminary. 
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Figure 6. 7 : Mean plasma TEARS in normoglycemic and chronically hyperglycemic mice. 
In normoglycemic NOD mice, plasma TEARS was 2.91 ± 0.62 p,M (n = 4). In NOD mice 
with chronic hyperglycemia, treated with subsistence-level insulin, plasma TEARS was 
4.31 ± 0.25 p,M (n = 4,p = 0.006 vs . normoglycemic). I n mice treated with EUK-207 in 
addition to subsistence-level insulin, plasma TEARS was 3.40 ± 0.74 p,M (n = 3). In mice 
treated with DNP in addition to subsistence-level insulin, plasma TBARS was 3.72 ± 0.24 
p,M (n = 3). 
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6.4 Discussion 
These results represent the first direct observations of the effects of acute and chronic 
hyperglycemia on the microvascular glycocalyx in vivo. Acute hyperglycemia ( < 4 
hours) did not result in an immediate decrease in the mean hydrodynamically relevant 
glycocalyx thickness. Substantial glycocalyx degradation was found after one week of 
untreated hyperglycemia or approximately three weeks of hyperglycemia treated with 
subsistence-level insulin therapy. Furthermore, it was observed that treatment with 
subsistence-level insulin therapy in combination with either the synthetic SOD/CAT 
mimetic, EUK-207, or the mitochondrial uncoupler, DNP, can reduce glycocalyx 
degradation in chronic hyperglycemia. These findings have implications for microvas-
cular complications associated with acute and chronic hyperglycemia, as well as po-
tential treatment strategies in type 1 and type 2 diabetes. 
Acute Hyperglycemia 
The hydrodynamically relevant glycocalyx thickness after an acute hyperglycemic 
clamp was not significantly less than that found in healthy, normoglycemic WT or 
NOD mice prior to developing diabetes. However, this does not necessarily imply 
that alterations in glycocalyx structure had not occurred, only that any changes that 
may have occurred over the course of the experimental period did not result in a 
detectable decrease in the mean hydrodynamically relevant glycocalyx thickness. Al-
though not statistically significant, the mean glycocalyx thickness in the acute group 
was rv 0.1 p..m less than in the normoglycemic group and the SD in the acute group 
was nearly twice that of the normoglycemic group. This suggests a greater hetero-
geneity in the glycocalyx thickness of the acute group, which could be indicative of 
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the beginnings of glycocalyx degradation. Given the high SD in the acute group, 
a larger sample size might be required to reveal any statistically significant differ-
ence in glycocalyx thickness that might exist. In a previous study, Nieuwdorp et al. 
[75], used an indicator-dilution method to estimate systemic glycocalyx volume in 
human males before and after a 6-hour hyperglycemic clamp. They reported a 50% 
reduction in glycocalyx volume. Although it is not known how closely this estimate 
reflects the actual magnitude of changes in glycocalyx volume or thickness [76], it 
does indicate that a decrease occurred. Taken together, these results suggest a pos-
sible timeline for the degradation of the glycocalyx in response to a single episode 
of acute hyperglycemia. This could have important implications for transient post-
prandial hyperglycemia excursions that inevitably arise in standard-care exogenous 
insulin therapy for diabetes. 
Recently, there has been much debate regarding the extent to which postprandial 
hyperglycemia contributes to long-term cardiovascular complications in people with 
diabetes [92] and whether strategies to minimizing these glycemic excursions should 
be pursued clinically [93]. If the integrity of the endothelial glycocalyx can be used 
as a metric for vascular health, then the results presented here would suggest that 
acute hyperglycemic excursions, lasting less than four hours, show no quantitative 
manifestations that vascular health is significantly compromised. However, recent 
studies have suggested that variability in BG levels could be a more important con-
tributor to vascular disease than mean glucose levels [94, 95]. Therefore, it should 
also be considered that while a single episode of acute hyperglycemia may not result 
in any immediately apparent damage to the vasculature, it is possible that repeated 
glycemic excursions of this nature could cumulatively contribute to EC dysfunction 
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and vascular pathology. 
It is possible that, in the case of acute hyperglycemia, ECs are initially able 
to synthesize glycocalyx at a rate sufficient to match, or nearly match, the rate of 
ROS-mediated degradation. However, it seems likely that, over time, increasing ROS-
mediated endothelial dysfunction would eventually prevent the cells from sustaining 
the rate of synthesis needed to maintain an intact glycocalyx. Alternatively, or in 
addition to this process, it might take several hours for the superoxide concentration in 
the blood to reach the levels necessary to significantly degrade the glycocalyx. If there 
were recurring episodes of acute hyperglycemia closely spaced in time, it is possible 
that superoxide levels in the blood could accumulate to levels sufficient to cause EC 
dysfunction. This could result in more rapid degradation of the glycocalyx with each 
successive episode of acute hyperglycemia. In a study by Potter et al., full restoration 
of the glycocalyx required up to seven days following enzymatic degradation and the 
WBC count remained elevated over the entire recovery period [15]. They likened this 
process of glycocalyx degradation and recovery to a wound-healing response over the 
denuded luminal surface of the vascular endothelium. Thus, even if an individual 
episode of acute hyperglycemia were to cause only a small amount of glycocalyx 
degradation, multiple episodes over a one-week period could result in accumulating 
degradation, as the glycocalyx would not have sufficient time to recover fully between 
episodes. 
Chronic Hyperglycemia 
In our studies of chronic hyperglycemia in NOD mice, we found that the mean hy-
drodynamically relevant glycocalyx thickness is rv 0.1 f.-liD after one week of uncon-
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trolled hyperglycemia and rv 0.2 ~-tm after three weeks of hyperglycemia treated with 
subsistence-level insulin therapy. In both cases,the mean glycocalyx thickness was 
significantly less than the rv 0.5 ~-tm mean glycocalyx thickness found in healthy nor-
moglycemic mice. In addition, the mean glycocalyx thickness in the mice treated 
with subsistence-level insulin therapy alone was not significantly different from that 
found in the untreated mice. A study by Nieuwdorp et al. [43] found a similar re-
duction in glycocalyx volume in individuals with type 1 diabetes using an indirect 
indicator-dilution method. They also found that individuals with type 1 diabetes and 
microalbuminuria showed an even greater decrease in glycocalyx volume. The results 
of these studies support our finding that longer periods of hyperglycemia result in 
significant glycocalyx degradation. 
There is evidence that the glycocalyx acts as a barrier to adhesion and is a nec-
essary component of the inflammatory response [12]. Given that pro-inflammatory 
conditions are one result of the overproduction of superoxide in response to hyper-
glycemia [20, 74], the observed degradation could be part of an ongoing inflammatory 
response. However, it is also possible that the degradation of the glycocalyx is the 
initiating event in this response. 
The level of glycocalyx degradation found here is similar to that reported in a 
study by Damiano et al. where fluorescent light-dye treatment was used to degrade 
the layer in venules of WT mouse [4]. In this treatment, a fluorescent dye was infused 
and allowed to distribute systemically throughout the circulation. Microvessels were 
then epi-illuminated for rv 5 minutes to induce degradation ofthe glycocalyx [1, 3]. M-
PIV was combined with microviscometric analysis to estimate the hydrodynamically 
relevant glycocalyx thickness. The mean hydrodynamically relevant glycocalyx thick-
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ness was reported to decrease from 0.5 ± 0.03 f-Lm (n = 10) before light-dye treatment 
to 0.2 ± 0.02 f-Lm(n = 9) after light-dye treatment (p < 0.05) [4]. When compared 
with the results from the present study, no statistically significant differences were 
found to exist between the mean glycocalyx t hickness observed in the control groups 
of these two studies, or between the mean glycocalyx t hickness observed between 
the light-dye-treated mice and t he untreated chronically hyperglycemic mice, or be-
tween the light-dye-treated mice and the chronically hyperglycemic mice t reated with 
subsistence insulin therapy alone. 
The first study to introduce light -dye treatment as a method for degrading the 
glycocalyx used a dye-exclusion method, rather than f-L-PIV, to estimate the gly-
cocalyx thickness before and after light-dye treatment of capillaries in the hamster 
cremaster muscle [1]. The dye-exclusion method estimated t he glycocalyx thickness 
as one-half of the difference between the anatomical diameter (AD) and functional 
diameter (FD) of a capillary. The AD corresponded to the diameter measured from 
a brightfield image of a capillary, whereas the FD was obtained by measuring the 
width of the column of the systemically circulating fluorescent dye within the same 
capillary. Henry and Duling [9] showed that, due to diffraction near t he vessel wall, 
the dye- exclusion method was limited to vessels with a small radius of curvature 
(vessels < 15 p,m in diameter). Using the dye-exclusion method, Vink and Duling [1] 
showed that the mean AD did not differ before and after light-dye treatment (4.8±0.2 
f-Lm) , but that the mean FD did (4.1 ± 0.2 f-Lm before vs. 4.6 ± 0.3 f-Lm after light-dye 
treatment, p < 0.05). They estimated that glycocalyx thickness, as defined by the 
difference between the AD and FD, decreased from "' 0.35 f-Lm before to rv 0.1 f-Lm 
after light-dye treatment, corresponding to a reduction of rv 70%. This is comparable 
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to the "" 60% reduction seen in the present study in venules of NOD mice after one 
week of untreated hyperglycemia and in the previously discussed study of Damiano 
et al. [4] in venules of WT mice after light-dye treatment. 
In addition to AD and FD, Vink and Duling [1] also observed that capillary hema-
tocrit (local vs. proximal) increased with FD. A 60% increase in capillary hematocrit 
was reported in vessels after light-dye treatment when compared to control vessels. 
They then treated the cremaster-muscle with SOD/CAT during light-dye treatment 
and reported no increase in capillary hematocrit as compared to control [1]. This sug-
gests that the glycocalyx degradation observed using light-dye treatment was medi-
ated by superoxide radicals generated by the interaction of light with the systemically 
circulating fiuorophores in the blood, and that these free radicals could be scavenged, 
thus preventing glycocalyx degradation, by co-treating with SOD/CAT. 
SOD/CAT and DNP Interventions 
Several previous studies have attempted to mitigate the effects of hyperglycemia 
with antioxidants, such as vitamins E and C, with varying levels of success [20, 74]. 
It was suggested by Brownlee that a synthetic SOD/CAT therapy, which mimics 
native compounds, might be more successful than traditional antioxidants [20]. The 
EC glycocalyx itself might provide a substrate upon which such a therapy could act. 
Heparan sulfate proteoglycans, thought to be a major constituent of the glycocalyx [6-
8], are known to contain binding sites for SOD [96], which could make the glycocalyx 
a reservoir for free-radical scavengers that would be readily accessible to the EC. This 
could allow for the SOD to not only scavenge ROS that have migrated out of the EC 
from degrading the glycocalyx, but would also make the SOD readily available for 
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transport into the cell) where it could scavenge ROS at the source) inhibiting the 
pathway that leads to endothelial dysfunction. 
When subsistence-level insulin therapy was combined with a continuous infusion 
of the synthetic SOD /CAT mimetic EUK-207) the glycocalyx was partially protected 
from degradation. In mice treated with EUK-207) the estimated mean hydrody-
namically relevant glycocalyx thickness was r-v 0.4 J..tm after a three-week period of 
sustained hyperglycemia. This is significantly thicker on average than the glycocalyx 
found in the chronically hyperglycemic NOD mice that were without insulin therapy 
or received only a subsistence-level insulin therapy) and did not receive SOD/CAT 
therapy. In mice treated with EUK-189) the mean glycocalyx thickness was found 
to be rv 0.3 J..tm) which was not significantly greater than that found in the group 
treat ed only with subsistence-level insulin therapy. Due to its cyclic structure (see 
Fig. 6.1)) EUK-207 is more biologically stable and has a longer plasma half-life than 
EUK-189 [81]. This could account for the outcome observed here. What is not known 
is whether EUK-207 only scavenges ROS outside of the EC or if it is able to pass 
through the cell membrane and scavenge ROS before they migrate out of the cell. 
If the SOD/CAT mimetic is not membrane soluble) the therapy would only protect 
against glycocalyx degradation from blood-borne free radicals) but it would not pre-
vent EC dysfunction resulting from hyperglycemia-induced ROS production within 
the cell. If treatment with SOD/CAT mimetics can both protect the glycocalyx from 
free-radical damage and reduce EC dysfunction in hyperglycemia) it has therapeu-
tic potential in the treatment of diabetes. Whereas the SOD /CAT mimetics used 
here must be administered subcutaneously) a new group of SOD/CAT mimetics have 
recently been developed that can be administered orally [83]. 
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Treatment with the mitochondrial uncoupler DNP in addition to subsistence-level 
insulin therapy was also protective of the glycocalyx, and resulted in a mean glyco-
calyx thickness of rv 0.4 p,m. This was thicker than that found in the group treated 
with insulin only and similar to that found in mice treated with EUK-207. The mech-
anism of action of DNP is much different from that of SOD/CAT. While SOD/CAT 
scavenges ROS that have already formed, DNP reduces ROS production in the mi-
tochondria by increasing mitochondrial electron transport and oxygen consumption 
[85]. Preventing excess levels of ROS from occurring could potentially circumvent 
the pathways leading to endothelial dysfunction in hyperglycemia; however, unlike 
SOD/CAT mimetics, DNP has little potential as a therapeutic agent to reduce the 
deleterious complications of hyperglycemia in diabetes. When it was first discovered, 
DNP was widely used as a weight-loss therapy, since one of its effects is to increase 
metabolism, but at sufficiently high doses it can cause fatal hyperthermia, in addi-
tion to several other reported side-effects [86]. Thus, if mitochondrial uncoupling is 
to be considered as a potential target in the treatment of hyperglycemia, alternative 
approaches will need to be considered [85]. 
Although EUK-207 and DNP were both protective against degradation of the 
glycocalyx, in both cases a statistically significant partial degradation was observed 
relative to the glycocalyx in healthy, normoglycemic mice. However, since treatment 
with SOD/CAT or DNP was not begun until one week after the onset of hyper-
glycemia and the beginning of subsistence-level insulin therapy, it is possible that 
some glycocalyx degradation had occurred prior to the start of SOD/CAT or DNP 
treatment. If this was the case, then it is plausible t hat either or both of these treat-
ments were completely protective of what remained of the glycocalyx at the time 
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SOD/CAT or DNP treatment began. In fact, it is also possible that either or both of 
these treatments may have actually allowed for partial recovery of the glycocalyx over 
the course of the treatment period. It was previously shown by Potter and Damiano 
[15] that the glycocalyx takes up to one week to fully recover after systemic enzy-
matic degradation. Therefore, it is possible that the SOD/CAT or DNP treatment 
could have completely protected the glycocalyx if the treatment had begun earlier, 
prior to the initial degradation, or if the treatment had been continued for a longer 
period, allowing more time for the glycocalyx to recover. On the other hand, since the 
subsistence-level insulin therapy was designed to maintain BG levels in these animals 
at 2-3 times greater than normal, it is also possible the SOD/CAT and DNP doses 
used here were not sufficient to completely mitigate the resulting oxidative stress. 
This is supported by the TBARS assay results , which suggest that although the lev-
els of oxidative stress in the EUK-207 and DNP groups were lower than in the group 
receiving subsistence-level insulin therapy alone, they were still higher than in the 
normoglycemic group. 
A long-term objective of this line of investigation is to ultimately develop a ther-
apy to augment insulin which could protect the vasculature from free-radical damage 
even in the presence of mild chronic hyperglycemia. If we could establish a therapeu-
tically safe and practical long-term administration of a combination therapy of insulin 
and SOD/CAT that prevents glycocalyx degradation, and in turn prevents microvas-
cular damage in the presence of mild chronic hyperglycemia, then the advantages of 
such an approach would be multifaceted and would represent a revolutionary turning 
point in the manner in which diabetes (and type 2 diabetes in particular) could be 
managed. In particular, such a therapy would obviate the need for tight glycemic 
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control, thus substantially reducing or eliminating exposure to hypoglycemia. This 
could also allow for relaxation of the current recommendations for glycemic control, 
which most individuals with type 1 diabetes fail to meet. Analysis of data from a sur-
vey of people with type 1 diabetes (NHANES, 1999-2000) indicated that only 37% 
were achieving the ADA recommended HbA1C levels < 7% [97]. _Despite ongoing 
improvements in technology and increasing emphasis on tight glycemic control, this 
percentage was not improved from an earlier survey (NHANES III, 1994-1998) [97]. 
FUrthermore, by raising the target BG, less insulin would be required than would 
be necessary to achieve near euglycemia. Reducing or eliminating hyperinsulinemia, 
which is a common complication of type 2 diabetes, would in turn reduce or eliminate 
chronic vascular complications that arise from hyperinsulinemia. Finally, since the 
SOD/CAT therapy would be scavenging excess free radicals generated by the mild 
chronic hyperglycemia, routine care would become much less onerous as the frequency 
of BG monitoring could be substantially reduced, which could increase patient com-
pliance with treatment recommendations. In order to achieve this ambitious goal, 
sophisticated animal studies would be required to study the efficacy and practicality 
of such a combination therapy in the management of diabetes. 
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Chapter 7 
Conclusions and Future Directions 
In this dissertation, Jlr PIV and microviscometric analysis were applied in vivo in 
arterioles and venules rv 20-70 JLm in diameter in the mouse cremaster muscle. Es-
timates of the hydrodynamically relevant glycocalyx thickness were obtained under 
various experimental conditions in order to explore fundamental questions regarding 
the structure and function of the endothelial-cell surface glycocalyx in normal and 
pathological states. To investigate the physiological significance and composition of 
the glycocalyx, experiments were performed in arterioles of WT mice and in venules of 
mice with genetically altered HSPG expression. To investigate the state of the glyco-
calyx, and its possible vasculoprotective role in health and disease, experiments were 
performed in venules of mice under conditions of acute and chronic hyperglycemia. 
Prior to this work, the presence of the glycocalyx in vivo had been established 
only in microvessels < 15 JLm in diameter [1, 9], and in venules rv 20-70 JLm in 
diameter [4, 5, 14], but not in arterioles > 15 JLm in diameter. In Chapter 4, JL-PIV 
and microviscometric analysis were adapted for use in arterioles. The main challenge 
in applying these methods in arterioles was the pulsatile nature of arteriolar blood 
flow. To address this, the acquisition of JL-PIV data was synchronized with the ECG 
of the mouse, allowing for data to be collected at specific time points in the cardiac 
cycle [44). Microviscometric analysis of JL-PIV data collected at a single point in the 
cardiac cycle revealed the presence of a hydrodynamically relevant glycocalyx in vivo 
that was rv 0.4 JLm thick in arterioles rv 20-70 JLm in diameter [42). This is slightly 
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thinner than the "' 0.5-,um-thick glycocalyx observed in venules of this size. Analysis 
of data collected in arterioles at four time points in the cardiac cycle indicated that 
glycocalyx thickness is constant throughout the cardiac cycle and does not fluctuate 
as a result of pulsatile flow. This indicates that in arterioles, as in venules, fluid shear 
stress present on the apical surface of the glycocalyx is transmitted to the EC through 
the solid matrix of the glycocalyx. Therefore, fluid shear stress essentially vanishes on 
arteriolar endothelium, as it has previously been shown to do on venular endothelium 
[4, 5] . This finding has important implications for understanding mechanisms of 
microvascular mechanotransduction in vivo. Although several previous studies have 
presumed the existence of an arteriolar glycocalyx similar to that found in venules, 
this was the first study to directly demonstrate its existence in vivo. 
With the establishment of a hydrodynamically relevant glycocalyx on arteriolar 
endothelium, similar in vivo methods can now be applied to further investigate the 
role of the glycocalyx in normal physiological processes and in pathological states, 
such as atherosclerosis, that preferentially impact arterioles. Future studies could 
also attempt to elucidate how glycocalyx composition and/ or structure might differ 
between arterioles and venules. Since the observed difference in glycocalyx thickness 
between arterioles and venules in the experiments presented here was not attributable 
to hemodynamic differences, there may be phenotypic differences between arteriolar 
and venular endothelium. It is also possible that functional or physiological differences 
other than hemodynamics may account for the observation. 
Although the glycocalyx has been the subject of many investigations and has been 
implicated in many physiological processes and pathological conditions, its structure 
and composition are still largely unknown. In the study presented in Chapter 5, ,u-PIV 
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and microviscometric analysis were applied in venules of mice deficient in syndecan-1, 
which has been thought to be one of the primary membrane-bound components of 
the glycocalyx. The hydrodynamically relevant glycocalyx thickness in Sdcl-/- mice 
was, on average, r-v 0.1 p,m thinner than that found in WT mice. Increased leukocyte 
adhesion was also observed in Sdc1-/- mice. Therefore, while syndecan-1 is not a 
prerequisite for the existence of the endothelial glycocalyx, syndecan-1 deficiency 
may alter glycocalyx composition, structure, and function. 
Of particular interest is how the absence of syndecan-1 might affect the role of the 
glycocalyx in inflammation. In WT mice, it has been established that after degrada-
tion, it takes up to seven days for a full recovery of the hydrodynamically relevant 
glycocalyx [15]. Throughout the recovery period, WBC counts remained elevated, 
and it was suggested by Potter and Damiano that the physiological implications of 
systemic degradation of the glycocalyx might be similar to a wound-healing response 
over the entire vascular endothelium [15]. Performing similar experiments in Sdcl-/-
mice might provide further insight into how the glycocalyx in these mice differs from 
that found in WT mice. Previous studies in Sdcl-/- mice have demonstrated that 
these animals are healthy under normal conditions, but when challenged with injury 
or disease, a variety of phenotypes become apparent, many of which point towards 
syndecan-1 as an important regulator of the inflammatory response [54, 55, 59-63]. 
The observed phenotypes include delayed healing and recovery, increased mortality, 
upregulation of certain integrins, cytokine, and adhesion molecules, and increased 
leukocyte adhesion. Therefore, it might be expected that the recovery time after 
glycocalyx degradation in these mice would be prolonged relative to WT mice, and 
accompanied by persistent inflammation and increased leukocyte activity. 
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Vascular disease arising from hyperglycemia has been strongly linked to oxida-
tive stress and EC dysfunction resulting from overproduction of superoxide by the 
mitochondrial electron transport chain [20, 21]. In addition to degradation of the 
glycocalyx in the presence of excess ROS, which was first observed by Vink and 
Duling [1], hyperglycemia-induced EC dysfunction could compromise the ability of 
ECs to synthesize glycocalyx components and maintain the integrity of the layer. In 
Chapter 6, experiments were performed to investigate the extent to which acute and 
chronic hyperglycemia degrade the glycocalyx. Acute hyperglycemia ( < 4 hours) did 
not result in immediate reduction in the hydrodynamically relevant glycocalyx thick-
ness. Chronic hyperglycemia (approximately three weeks) in NOD mice resulted in 
degradation of the glycocalyx to rv 0.1-0.2 J-Lm in thickness. This is consistent with 
the level of degradation observed after light-dye treatment, which is thought to be 
caused by oxidative stress [1]. 
After establishing that chronic hyperglycemia results in glycocalyx degradation, 
further experiments were performed to test whether this degradation can be mitigated 
by treatments aimed at reducing levels of ROS and normalizing EC function. Treat-
ment with the synthetic SOD/CAT mimetic EUK-207 or the mitochondrial uncou-
pler DNP, in combination with subsistence-level insulin therapy, reduced, but did not 
completely prevent glycocalyx degradation in the presence of chronic hyperglycemia. 
Preliminary results of TBARS assays are consistent with this finding. Plasma TBARS 
levels were highest in the hyperglycemic group receiving only subsistence-level insulin 
therapy. Levels in the groups also receiving treatment with SOD/CAT or DNP were 
lower than the insulin-only group, but still higher than in normoglycemic mice. 
While the work presented here establishes that the glycocalyx is degraded during 
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hyperglycemia, and that treatment with SOD/CAT mimetics or DNP can be pro-
tective of the glycocalyx, it does not directly link protection of the glycocalyx to 
improved vascular health. Further experiments would be required to prove the hy-
pothesis that preserving the hydrodynamically relevant thickness of the glycocalyx 
is sufficient to protect the vasculature. It would also be of interest to investigate 
whether SOD/CAT or DNP treatment are able to preserve the glycocalyx over even 
longer periods of hyperglycemia than those studied here. 
A long-term objective of this line of investigation would be to develop a therapy 
to augment insulin, which could protect the vasculature from oxidative damage even 
in the presence of mild chronic hyperglycemia. While treatment with EUK-207 and 
similar compounds may have therapeutic potential, DNP does not, as it can cause 
potentially fatal side-effects in humans. However, these experiments do demonstrate 
that reduction of mitochondrial superoxide production with a mitochondrial uncou-
pler could provide benefits similar to those achieved with free-radical scavengers. If 
a safe therapeutic delivery of a mitochondrial uncoupler could be developed, it could 
be considered as a potential preventative therapy against deleterious complications 
of chronic hyperglycemia. 
A necessary step in the development of any therapy would be to perform exper-
iments in higher-order animal models. Newer formulations of synthetic SOD/CAT 
mimetics have been developed that are orally available; these could facilitate further 
experiments in this area. There is also the question of how to evaluate glycocalyx 
integrity in large animals, as the {L-PIV method would not be practical. One possi-
bility is the indicator-dilution method, which has been used previously in an attempt 
to assess glycocalyx volume in humans [43, 75), but further validation of this method 
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will be required for it to be considered a reliable indicator of glycocalyx volume [76]. 
The existence of a thin non-cellular layer on the luminal surface of the vascular 
endothelium was first hypothesized over 70 years ago [23], but it was not until after 
the first in vivo visualization of the glycocalyx in 1996 [1], which showed the it to be 
much more substantial than had previously been revealed by EM, that it began to re-
ceive considerable research attention. Since then, the glycocalyx has been the subject 
of numerous investigations, which have provided evidence that it plays many roles in 
cardiovascular physiology; however, the structure, composition, and precise mecha-
nistic roles of the glycocalyx remain largely hypothetical. Given that damage to the 
glycocalyx has been implicated in multiple vascular pathologies, such as atheroscle-
rosis, ischemia/reperfusion injury, and vascular disease resulting from diabetes, the 
presence of an intact glycocalyx may be critical to vascular health. 
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Appendix A 
Mathematica Code for Microviscometric Analysis 
This is a modification of the original Mathematica code for microviscometric analysis 
of ,u-PIV data, written by Long [98], following the method described by Damiano et 
al. [4]. 
Rheological Study of Microvessels in vivo 
This is the main portion of the analysis code. Functions in bold are defined in the 
sections following, in the order they are called here. All variables are in italics. 
b = 0.454/ 2; (*radius of microspheres, green = 0.538, red = 0.513 or 0.454 tLm*) 
stepsize = 0.01; (*step size between each trial glycocalyx thickness, /Lm*) 
K = oo; (*hydraulic resistivity value, dyn-s/ cm4*) 
,Uplasma= 0.0122483; (*viscosity of plasma at 37°C, dyn-s/cm2 *) 
X = 1; (*scale factor between viscosity at vessel wall and viscosity of plasma*) 
f..lwall = X* ,Uplasma; (*viscosity at vessel wall*) 
Do[ 
SetDi rectory[pathread]; 
data file = ToString[filelist[[j]]]; 
datal D = StringTake[ToString[filelist[[j]]], Stringlength[datafile] - 4]; 
pivdata = lmport[datafile , 'Table"]; 
{pivdata1, pivdata2, pivdata,R} = AxiSym[pivdata]; 
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mfdata = MonotonicFilter(pivdata]; 
fittable = {}; 
t = 0; (*trial glycocalyx thickness*) 
tmax = Round[R- (Max[mfdata [[AII, 1]]] + b), stepsize]; (*maximum thickness if f..L-
spheres cannot invade layer*) 
While[t <= tmax• 
{error, a, V, f-Lrel, fpvdata} = FitMicroPIVData[Take[mfdata, All, 2], R, tmax. r, 
t]; 
AppendTo[fittable, error, t, a, V, f-Lrez, fpvdata]; 
t = t + stepsize; 
] ; (*find best-fit velocity profiles for a range of glycocalyx thicknesses, also returns associated 
error, viscosity profile, and fluid-particle velocity data*) 
{ minerror, t, a, V, f-Lrez, fpvdata} = First[Sort[fittable]]; (*get fit with minimum error*) 
fittable[[AII, 1]] = fittable[[AII, 1]] /minerror; (*normalize error*) 
estar = Reverse[Sort[Take[fittable, All, 2]], {1, 2}]; 
{Vavg• Q} = FlowRate[V, R, a]; 
dpdz = PressureGradientLV[V, R, a, f-Lwazzl; 
7Jrel = RelativeApparentViscosityLV[P,reZ, R, a ]; 
ry = MakePureFunction[r, Fui1Simplify[1/ R D[V [r], r]]]; (*shear rate*) 
T = MakePureFunction[r, FuiiSimplify[-P,wall * f-Lrez[r] * ry [r]]]; (*shear stress, should be 
linear*) 
Vp = MakePureFunction[r, (1- r 2)V[O]]; (*parabolic velocity profile with same centerline 
velocity as V and no glycocalyx*) 
dpdzp = PressureGradientLV[Vp, R, 1, f-twazz]; 
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"yp = MakePureFunction[r, Fui1Simplify[1 / R D[Vp [r], r ]]]; 
Tp = MakePureFunction[r , FuiiSimplify[-Mwall * fLrez[r] * "'fp [r ]]] ; 
,{j, 1, Length[fiZeZist]}]; (*end Do loop*) 
AxiSym Function 
This funct ion takes data that was measured from the vessel wall and changes the 
origin to the vessel centerline and folds the data onto 1/2 of the vessel cross-section. 
It also sorts the data based on which wall of the vessel it was originally measured 
from, so that axisymmetry of the data can be verified. 
AxiSym[alldata_] := Module[{R, data, centerline, n, wall 1, wall2 }, 
R = alldata [[1 , 1 ]] / 2; (*vessel radius*) 
data = Drop[alldata, 1] ; 
data = Sort[Transpose[Part[Transpose[data], {9, 5, 2, 1 }]]]; (*Sort data by absolute Y-
position of vessel wall*) 
data[[AII, 2]] = R- data[[AII, 2]]; (*data measured from vessel centerline*) 
centerline = (First[data[[AII , 1]]] + Last[data[[AII, 1]]])/ 2; (*Location of vessel center-
line*) 
n = Length[Select[data[[AII , 1]], # <centerline&]]; 
data= Transpose[Part[Transpose[data], {2, 3}]] ; 
wall1 = Take[ data, n, All]; (*data measured from wall 1 *) 
walll[[AII, 1]] = - walll [[AII , 1]]; 
wall2 = Take[data, n- Length[data], All]; (*data measured from wall 2*) 
data = Join[walll , wall2]; 
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data[[AII, 1]] = Abs[data[[AII, 1]]]; (*data folded onto 1/2 cross-section*) 
data= Sort[data]; 
Return[ { walll, wall2, data, R}]; 
] ; 
MonotonicFilter Function 
This function monotonically filters the data, keeping only the beads that have a 
velocity greater than all other beads with a radial position (as measured from the 
centerline) less than or equal to their own. This is done in recognition of the fact 
that t he microsphere velocities decrease monotonically with increasing radial position, 
therefore the microspheres traveling in the midsagittal plane of the vessel will have 
the greatest velocities[3]. 
MonotonicFilter[data_] := Module[{ sdata, maxvel, lac, mfdata, i} , 
sdata = Sort[data]; 
maxvel = Max[sdata[[AII. 2]]]; 
lac = Last[Fiatten[Position[sdata[[AII, 2]].maxvel]]]; (*find location of data point with 
maximum velocity*) 
mfdata = Reverse[Drop[sdata, 1, loc- 1]]; 
Do[ 
if[mfdata[[2. 2]] j= mfdata[[1. 2]]. 
mfdata = Drop[mfdata. 2]; ,(*If the velocity of the 2nd microsphere, which is closer to 
the vessel centerline, is less than the 1st, drop the 2nd microsphere*) 
mfdata = Rotateleft[mfdata]; (*otherwise, drop nothing and move the 1st microsphere 
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to the end of the list*) 
] ; (*end If statement*) 
lf[mjdata [[1, 2]] == maxvel, 
Break[]; (*continue filtering data until point with maximum velocity is reached, at this 
point filtering is complete*) 
] ; , (*end If statement*) 
{i, 1, 50 Length[mjdata]}]; (*end Do loop*) 
mjdata = Sort[mjdata]; 
Return[mjdata]; 
] ; 
FitMicroPIVData Function 
This function finds the best fit to the j.l-PIV data for K - oo and a given trial 
glycocalyx thickness, using nonlinear regression analysis. 
FitMicroPIVData[pivdata_, R_, tmax-· r _, L] := 
Module[{a, jpvdata, rpiV> VpiV> june, e, j, Vmax, O", V, eoej j, vfit, error, i, v,n, J.ltn}. 
a= 1- (tj R); (*nondimensional radial location of interface*) 
jpvdata = FluidParticleVelocities[pivdata, R, t, b,]; 
rpiv = First[Transpose[jpvdata]] / R; (*nondimensional radial coordinates*) 
Vpiv = Last[Transpose[jpvdata]]; (*fluid particle velocities*) 
june= ((1-e Sinh[ja ]) # 1 + ae Sinh[#1j]&); (*fitting function, e and f will be found 
through nonlinear regression analysis*) 
Vmax = (vpiv (lntegrate[june[O"].{O", 0, a}])) / lntegrate[june[O"],{O", rpiv, a ]}]; (*compute 
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Vmax for each data point*) 
Vmax = Length[Vmax]- 1 Plus Vmax; (*take average of all Vmax values computed above*) 
V = Vmax/ lntegrate[ func[O" ], { O", 0, a} ](lntegrate[func [O"], { O", r, a}]); (*fit data to June 
using nonlinear regression to find e and f*) 
coef f= BestFitParameters j . NonlinearRegress[Transpose[{rpiv, Vpiv} ]. V, {r }, { e, f}, 
RegressionReport -+ BestFitParameters, Maxlterations -+ 500]; (*this gives e and f in 
substitution format*) 
Vfit = V j.coef f; (*substitute e and fin V*) 
error= PlusTable[((VJit/.r-+ rpiv[[i]]) - Vpiv[[i]]) 2 , {i, Length[rpiv]}]; (*calculate the 
sum of squared errors between the data and the fit*) 
Vfn = MakePureFunction[r, FuiiSimplify[VJit]]; (*fluid velocity in lumen as a function of 
normalized radial position*) 
1-LJn = MakePureFunction[r, r / afunc[r]-1 j.coef f ]; (*viscosity distribution relative to vis-
cosity at the vessel wall*) 
Return[{ error, a, Vfn, /-Lfn, fpvdata }]; 
]; 
FluidParticle Velocities Function 
This function calculates the fluid particle velocities from the ,u-PIV data, forK= oo 
and a given trial glycocalyx thickness. The variable Ulimitdata is the data generated 
from the exact series solut ions for the free motion of a neutrally buoyant sphere above 
an impermeable surface [35] . 
FluidParticleVelocities[data_, R _, t_, a_] :=Module[{U, r, H , june, i, fpv ={} }, 
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U = Last[Transpose[Sort[data]]]; 
r = First[Transpose[Sort[data]]] ; 
H = R- r; (*transform r--+ z-coordinates where z = 0 is blood-glycocalyx interface*) 
june = lnterpolation[Transpose[{First[Transpose[UlimitD ata]] + tja, 
Last[Tra nspose[UlimitD ata]]})] ; 
xmax = Cosh[Log[lOO * 10- 1)]; 
Do[ 
lf[(H [[i]]/a) < = xmax , 
AppendTo[fpv, {r [[i]], U[[i]]func[H[[i]]/at 1}];, 
AppendTo[fpv, {r[[i]], U[[i]]}]; 
];, (*end If statement*) 
{ i, 1, Length[H]}]; (*end Do loop*) 
Return[fpv]; 
] ; 
FlowRate Function 
This function calculates the average velocity and volumetric flow rate in t he vessel. 
FlowRate[V _, R_, a_] :=Module[{Vav9 ,Q,r} , 
Vavg = 2 Nlntegrate[V [r ]r, {r, 0, a}] ; (*p,m/s*) 
Q = 1f R 2Vavg ; (*p,m3 /s*) 
Return[{Vavg, Q}]; 
]; 
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PressureGradientLV Function 
This function calculates the axial pressure gradient in the vessel. 
PressureGradientlV[V _, R_, a_, J..l-] :=Module[{ dpdz, r }, 
dpdz = 104 (2J..L/ R2)Limit[D[V[r], r]. {r ----7 a}][[l]]; (*dyn/cm3*) 
Return[dpdz]; 
] ; 
RelativeApparent Viscosity LV Function 
This function calculates the relative apparent viscosity, defined as the ratio Q p j Q, 
where Qp = -nR4 (dpdz)/(8J..lR) is t he volume-flow rate for Poiseuille flow of a fluid 
having constant viscosity, J..lR [4]. 
RelativeApparentViscositylV[J..l-, R_, a_] :=Module[{ 'Tlrez, r, O" }, 
'Tlrel = (8 Nlntegrate[lntegrate[O"/J..l [O"], {J,r,a}] r, {r,O,a}])-1 ; 
Return h rezl; 
] ; 
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A p pendix B 
Results of J.L-PIV and Microviscometric Analysis in Arterioles of WT 
Mice 
B .l Control Conditions, Single Time Point in the Cardiac Cycle 
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F igure B .l: Results from a 38.5-j.Lm-diameter arteriole, under control conditions. Shown 
in (A) are intravital fluorescent j.L-PIV data (symbols) collected at the same time point in the 
cardiac cycle and the corresponding predicted axisymmetric velocity profile extracted from 
the data (curve). The shaded region near the vessel wall represents the hydrodynamically 
relevant endothelial glycocalyx, R- a= 0.47 f.Lm. The local blood viscosity profile, relative 
to plasma viscosity, is shown in (B). Shown in (C) is the variation, relative to trial glycocalyx 
thicknesses, in the normalized least-squares error, E* , associated with the fit to the j.L-PIV 
data shown (A) . The estimated glycocalyx thickness is indicated by the black arrow. The 
shear rate (solid line) and shear stress (dashed line) profiles are shown in (D) . 
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Figure B .2: Same as Fig. B.l , except D = 61.2 p,m and R - a = 0.28 p,m. 
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Figure B.3: Same as Fig. B.l, except D = 46.7 p,m and R- a = 0.29 p,m. 
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Figure B .4: Same as Fig. B.l, except D = 42.0 f.-LID and R - a = 0.39 f.-LID. 
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Fig ure B .5: Same as Fig. B .l, except D = 44.3 f.-LID and R- a = 0.34 f.-LID. 
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Figure B .6: Same as Fig. B.l, except D = 39.7 J..Lffi and R - a= 0.15 J..Lffi . 
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Figure B.7: Same as Fig. B .l, except D = 46.0 J..Lffi and R- a = 0.27 J..Lm . 
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Figure B.8: Same as Fig. B .l , except D = 56.2 J.i,m and R- a = 0.61 J.i,m. 
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Figure B .9: Same as Fig. B.l , except D = 37.3 J.i,m and R- a = 0.39 J.i,m. 
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Fig ure B . lO: Same as F ig. B .l , except D = 23 .3 J.lm and R - a = 0.49 J.lm. 
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Figure B.ll: Same as F ig. B .l , except D = 30.3 J.lm and R - a = 0.24 J.lm . 
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B.2 Control Conditions, Four Time Points in the Cardiac Cycle 
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Figure B.l2 
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Figure B.12: Results from a 35.3-J.tm-diameter arteriole at four time points in the cardiac 
cycle, under control conditions. Shown in the left column are intravital fluorescent J.t-PIV 
data (symbols) and the corresponding predicted axisymmetric velocity profiles (curves) 
extracted from the data. The shaded region represents the glycocalyx. The inset shows the 
time point in the cardiac cycle where the data were collected (vertical arrow). The five data 
sets were collected over a period of "'15 minutes, with set A being collected first and set A' 
being collected last. Shown in the right column is the variation, relative to trial glycocalyx 
thicknesses, in the normalized least-squares error, E* , associated with the fit to the J.t-PIV 
data. The estimated hydrodynamically effective thickness for each data set is indicated by 
the arrow. The corresponding viscosity, shear rate, and shear stress profiles are shown in 
Fig. B.l3 . 
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Figure B.13: Results from a 35.3-p,m-diameter arteriole at four time points in the cardiac 
cycle, under control conditions. Shown in the left column are local blood viscosity profiles, 
relative to plasma viscosity. Shown in the right column are the shear rate (solid line) 
and shear stress (dashed line) profiles. The corresponding velocity profiles are shown in 
Fig. B.l2. 
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Figure B .l 4 : Same as Fig. B.l2, except D = 38.4 J.lffi. The corresponding viscosity, shear 
rate, and shear stress profiles are shown in Fig. B .l5. 
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Figur e B.15: Same as Fig. B.l3, except D = 38.4 J.Lm. The corresponding velocity profiles 
are shown in Fig. B.l4. 
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F ig u re B .16: Same as Fig. B.l2, except D = 38.9 f.LID . The corresponding viscosity, shear 
rate, and shear stress profiles are shown in Fig. B .l7. 
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F igure B .17: Same as Fig. B.l3, except D = 38.9 J.Lffi. The corresponding velocity profiles 
are shown in Fig. B .l6. 
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F igure B .20: Same as Fig. B.l2, except D = 31.7 p,m. The corresponding viscosity, shear 
rate, and shear stress profiles are shown in Fig. B.21. 
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Figure B.21: Same as Fig. B.13, except D = 31.7 p,m. The corresponding velocity profiles 
are shown in Fig. B.20. 
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Figure B.22: Same as Fig. B.l2, except D = 35.3 f-LID. The corresponding viscosity, shear 
rate, and shear stress profiles are shown in Fig. B.23. 
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Figur e B.23: Sarne as Fig. B.l3, except D = 35.3 p,m. The corresponding velocity profiles 
are shown in Fig. B.22. 
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Figure B.24: Same as Fig. B .l2, except D = 28.7 J.Lm . The corresponding viscosity, shear 
rate, and shear stress profiles are shown in Fig. B.25. 
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Figu re B .25: Same as Fig. B.l3, except D = 28.7 jJ,ffi. The corresponding velocity profiles 
are shown in Fig. B .24. 
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B.3 Hyaluronidase Treated, Single Time Point in the Cardiac Cycle 
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Figure B.26: Results from a 54.2-J.Lm-diameter arteriole, after hyaluronidase treatment. 
Shown in (A) are intravital fluorescent J.L-PIV data (symbols) collected at the same time 
point in the cardiac cycle and the corresponding predicted axisymmetric velocity profile 
extracted from the data (curve) . The shaded region near the vessel wall represents the 
hydrodynamically relevant endothelial glycocalyx, R - a = 0.00 J.Lm. The local blood 
viscosity profile, relative to plasma viscosity, is shown in (B). Shown in (C) is the variation, 
relative to trial glycocalyx thicknesses, in the normalized least-squares error , E*, associated 
with the fit to the J.L-PIV data shown (A). The estimated glycocalyx thickness is indicated 
by the black arrow. The shear rate (solid line) and shear stress (dashed line) profiles are 
shown in (D). 
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Figure B.27: Same as Fig. B.26, except D = 39.3 J..LID and R- a = 0.07 f..LID . 
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Figure B.28: Same as Fig. B.26, except D = 27.7 J..LID and R- a= 0.03 J..LID. 
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Figure B.29: Same as Fig. B.26, except D = 44.1 p,m and R- a = 0.00 p,m. 
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Figure B.30: Same as Fig. B.26, except D = 39.7 p,m and R- a= 0.00 p,m. 
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Figure B .31: Same as Fig. B.26, except D = 27.8 f.J-ID and R- a = 0.00 f.J-ID. 
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Figure B.32: Same as Fig. B.26, except D = 26.7 f.J-ID and R- a= 0.00 f.J-ID. 
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Appendix C 
11--PIV and Microviscometric Analysis in Venules of WT Mice 
C.l Normal Conditions 
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Figure C.l: Results from a 42.4-,um-diameter venule in a WT mouse, under normal 
conditions. Shown in the top left panel are raw intravital fluorescent ,u-PIV data (gray 
symbols), the monotonically filtered ,u-PIV data (black symbols), and the corresponding 
predicted axisymmetric velocity profile extracted from the data (curve). The shaded region 
near the vessel wall represents the hydrodynamically relevant endothelial glycocalyx, R- a 
= 0.51 ,urn. The variation, relative to trial glycocalyx thicknesses, in the normalized least-
squares error, E*, associated with the fit to the ,u-PIV data is shown in the top right panel. 
The predicted shear rate profile is shown in the bottom left panel, and the predicted local 
blood viscosity profile, relative to plasma viscosity, is shown in the bottom right . 
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Figure C.2: Same as Fig. C.l, except D = 21.3 p,m and R- a = 0.59 p,m. 
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Figure C.3: Same as Fig. C.l , except D = 31.4 p,m and R- a= 0.52 p,m. 
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Figure C .4: Same as Fig. C.l, except D = 26.8 p,m and R- a = 0.46 p,m. 
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Figure C.5: Same as Fig. C. l , except D = 31.8 p,m and R - a= 0.60 p,m. 
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Figure C.6: Same as Fig. C.l, except D = 43.7 J.Lm and R - a = 0.50 J.Lm. 
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F igure C.7: Same as F ig. C. l , except D = 38.2 J.Lm and R - a= 0.39 J.Lm. 
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Figure C.8: Same as Fig. C.l, except D = 25.9 J.Lm and R - a = 0.57 J.Lm . 
• 1.25 
• 
~ 1500 1.20 
"' • -...... • s • •• 3 1000 * 1.15 • • • • >.t.l 
>:' • 1.10 • • ~ 500 1.05 
0 1.00 0 5 10 15 20 25 30 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 
r (jim) R-a (jim) 
700 7 
600 6 ~ 500 
"' ~ -...... 5 ,....; 400 ~ '--' s 300 >:' 4 
·?-.. 200 '::( 3 
100 2 
0 1 0 5 10 15 20 25 30 0 5 10 15 20 25 30 
r (jim) r (jim) 
Figure C.9: Same as Fig. C.l, except D = 60.3 J.Lm and R- a = 0.78 J.Lm. 
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Fig ure C.lO: Same as F ig. C.l , except D = 57.9 p,m and R - a = 0.37 p,m. 
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Fig ure C.ll: Same as Fig. C.l, except D = 63.6 p,m and R - a = 0.69 p,m. 
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C .2 After Hyaluronidase Treatment 
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F igure C .12: Results from a 50.1-p,m-diameter venule in a WT mouse, after hyaluronidase 
treatment. Shown in the top left panel are raw intravital fluorescent p,-PIV data (gray 
symbols), the monotonically filtered p,-PIV data (black symbols), and the corresponding 
predicted axisymmetric velocity profile extracted from the data (curve). The shaded region 
near t he vessel wall represents the hydrodynamically relevant endothelial glycocalyx, R- a 
= 0.04 p,m. The variation, relative to trial glycocalyx thicknesses, in the normalized least-
squares error, associated with the fit to the p,-PIV data is shown in the top right panel. 
The predicted shear rate profile is shown in the bottom left panel, and the predicted local 
blood viscosity profile, relative to plasma viscosity, is shown in the bottom right . 
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Figure C.l3: Same as Fig. C.l2, except D = 26.0 J.Lm and R- a= 0.00 J.Lm. 
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Figure C.14: Same as Fig. C.l2, except D = 22.9 J.Lm and R- a= 0.11 J.Lm. 
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Figure C.l5: Same as Fig. C.12, except D = 55.3 p,m and R - a= 0.02 p,m. 
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Figure C.16: Same as Fig. C.12, except D = 26.9 p,m and R- a= 0.00 p,m. 
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Figure C.17: Same as Fig. C.12, except D = 50.7 f.LID and R- a= 0.00 J.LID. 
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A ppendix D 
tt-PIV and Microviscometric Analysis in Venules of Sdcl- /- Mice 
D .l Normal Conditions 
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Figure D.l: Results from a 53.8-p,m-diameter venule in a Sdcl-/- mouse, under normal 
condit ions. Shown in the top left panel are raw intravital fluorescent p,-PIV data (gray 
symbols), the monotonically filtered p,-PIV data (black symbols), and the corresponding 
predicted axisymmetric velocity profile extracted from the data (curve). The shaded region 
near the vessel wall represents the hydrodynamically relevant endothelial glycocalyx, R- a 
= 0.45 p,m. The variation, relative to trial glycocalyx thicknesses, in the normalized least-
squares error, E*, associated with the fit to the p,-PIV data is shown in the top right panel. 
The predicted shear rate profile is shown in the bottom left panel, and the predicted local 
blood viscosity profile, relative to plasma viscosity, is shown in the bottom right. 
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Figure D .2: Same as Fig. D.l, except D = 35.4 f.-LID and R- a= 0.28 f.-LID . 
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Figure D.3 : Same as Fig. D.l, except D = 29.7 f.-LID and R - a = 0.45 J..LID. 
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Figure D.4: Same as Fig. D.l, except D = 25.9 11m and R- a= 0.45 J.1m. 
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Figure D.5: Same as Fig. D.l, except D = 40.7 11m and R- a = 0.47 J.1m. 
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Figure D.6: Same as Fig. D.l, except D = 2.4 p,m and R- a = 0.45 p,m. 
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Figure D.7: Same as Fig. D.l, except D = 33.0 p,m and R- a = 0.51 p,m. 
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Figure D.8: Same as Fig. D.1 , except D = 22.1 J.Lm and R - a = 0.29 J.Lm . 
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Figure D.9: Same as Fig. D.1 , except D = 22.4 J.Lm and R - a = 0.50 J.Lm . 
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Figure D.lO: Same as F ig. D.l , except D = 33.4 J..l.m and R- a = 0.35 J..l.m . 
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Fig ure D.ll: Same as F ig. D.l , except D = 29.8 J..l.m and R - a = 0.69 J..l.m. 
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F igure D .l 2: Same as F ig. D.l, except D = 37.7 p,m and R- a= 0.37 p,m. 
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Figure D .13: Same as Fig. D. l, except D = 39.4 p,m and R- a = 0.50 p,m. 
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Figure D.14: Same as Fig. D .l, except D = 25.1 f.-LID and R- a = 0.42 f.-LID. 
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Figure D .15: Same as Fig. D.l , except D = 37.9 f.-LID and R - a = 0.50 f.-LID . 
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D.2 After Hyaluronidase Treatm ent 
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Fig ure D.16: Results from a 39.9-J.Lm-diameter venule in a Sdcl-/- mouse, after 
hyaluronidase treatment. Shown in the top left panel are raw intravital fluorescent J.L-
P IV data (gray symbols), t he monotonically fi ltered J.L-PIV data (black symbols), and the 
corresponding predicted axisymmetric velocity profile extracted from the data (curve). T he 
shaded region near the vessel wall represents the hydrodynamically relevant endothelial 
glycocalyx, R - a = 0.00 J.Lm. T he variat ion, relative to trial glycocalyx thicknesses, in the 
normalized least-squares error, E *, associated with the fit to the J.L-P IV data is shown in the 
top right panel. The predicted shear rate profile is shown in the bottom left panel , and the 
predicted local blood viscosity profile, relative to plasma viscosity, is shown in the bottom 
right . 
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Figure D.17: Same as Fig. D .16, except D = 32.5 p,m and R- a= 0.00 p,m. 
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Figure D.18: Same as Fig. D.l6, except D = 24.3 p,m and R- a = 0.05 p,m. 
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F igure D .19: Same as Fig. D.16, except D = 27.6 J.Lm and R - a= 0.06 J.Lm. 
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Figure D.20: Same as Fig. D. l 6, except D = 31.4 J.Lm and R - a = 0.00 J.Lm. 
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Figure D .21: Same as Fig. D.16, except D = 48.2 p,m and R - a= 0.00 p,m. 
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Figure D .22: Same as Fig. D.16, except D = 25.3 p,m and R - a= 0.07 p,m. 
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A ppendix E 
fl,-PIV and Microviscometric Analysis in Hyperglycemic Mice 
E .l Normoglycemic N OD Mice 
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Figure E .l : Results from a 26.3-f,Lm-diameter venule in a normoglycemic mouse. Shown 
in the top left panel are raw intravital fluorescent f,L-PIV data (gray symbols), the monoton-
ically filtered f,L-PIV data (black symbols), and the corresponding predicted axisymmetric 
velocity profile extracted from the data (curve) . The shaded region near the vessel wall 
represents the hydrodynamically relevant endothelial glycocalyx, R- a = 0.46 fLm. The 
variation, relative to trial glycocalyx thicknesses, in the normalized least-squares error, E*, 
associated with the fit to the f,L-PIV data is shown in the top right panel. The predicted 
shear rate profile is shown in the bottom left panel, and the predicted local blood viscosity 
profile, relative to plasma viscosity, is shown in the bottom right. 
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Figure E. 2: Same as Fig. E .l, except D = 22.5 f..Lill and R - a = 0.52 f..LID . 
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Fig ure E.3 : Same as F ig. E. l , except D = 43.4 f..Lill and R - a = 0.42 f..Lill. 
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Figure E.4: Same as Fig. E.l, except D = 41.2 J.Lm and R- a = 0.42 J.Lm. 
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E.2 Acutely Hyperglycemic WT and NOD Mice 
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Figure E.5: Results from a 34.2-J..Lm-diameter venule in a WT mouse with acute hy-
perglycemia. Shown in the top left panel are raw intravital fluorescent J..L-PIV data (gray 
symbols), the monotonically filtered J..L-PIV data (black symbols), and the corresponding 
predicted axisymmetric velocity profile extracted from the data (curve). The shaded region 
near the vessel wall represents the hydrodynamically relevant endothelial glycocalyx, R- a 
= 0.37 J..Lm. The variation, relative to trial glycocalyx thicknesses, in the normalized least-
squares error, E*, associated with the fit to the J..L-PIV data is shown in the top right panel. 
The estimated hydrodynamically effective thickness of t he glycocalyx corresponds to the 
value of R - a associated with the local minimum in this curve. The predicted shear rate 
profile is shown in the bottom left panel, and the predicted local blood viscosity profile, 
relative to plasma viscosity, is shown in the bottom right . 
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Figure E.6: Same as F ig. E.5, except D = 34.2 J..Lm and R - a = 0.38 J..Lm . 
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F igure E.7: Same as F ig. E .5, except D = 44. 5 J..Lm and R - a = 0.36 J..Lm . 
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Figure E .8: Same as Fig. E .5, except D = 30.3 f.-liD and R - a = 0.62 f.-liD. 
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Fig ure E.9: Same as Fig. E.5, except D = 31.8 f.-liD and R- a = 0.21 f.-liD. 
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Figure E .lO: Same as Fig. E .5, except NOD mouse, D = 23.3 p,m and R- a = 0.57 p,m. 
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Fig ure E .ll: Same as Fig. E.5 , except NOD mouse, D = 54.8 p,m and R- a = 0.75 p,m. 
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Figure E.12: Same as Fig. E.5, except NOD mouse, D = 45.4 ,u,m and R- a = 0.28 ,u,m. 
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Figure E.l3: Same as Fig. E .5, except NOD mouse, D = 46.5 ,u,m and R- a = 0.24 ,u,m. 
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E .3 N OD M ice w ith U ntreated Chronic Hyperglycemia 
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F igure E.l4: Results from a 21.2-J.Lm-diameter venule in a NOD mouse with untreated 
chronic hyperglycemia. Shown in the top left panel are raw intravital fluorescent J.L-PIV 
data (gray symbols), the monotonically filtered J.L-PIV data (black symbols), and the cor-
responding predicted axisymmetric velocity profile extracted from the data (curve) . The 
shaded region near the vessel wall represents the hydrodynamically relevant endothelial 
glycocalyx, R- a = 0.16 J.Lm. The variation, relative to trial glycocalyx thicknesses, in the 
normalized least-squares error, E *, associated with the fit to the J.L-PIV data is shown in 
the top right panel. The estimated hydrodynamically effective thickness of the glycocalyx 
corresponds to the value of R - a associated with the local minimum in this curve. The 
predicted shear rate profile is shown in the bottom left panel , and the predicted local blood 
viscosity profile, relative to plasma viscosity, is shown in the bottom right. 
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Figure E.15: Same as Fig. E.14, except D = 26.7 J-tm and R- a = 0.00 J-tm. 
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Figure E.16: Same as Fig. E.14, except D = 32.3 J-tm and R- a= 0.09 J-tm. 
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Figure E. 17: Same as Fig. E.14, except D = 27.6 /-Lm and R- a= 0.18 fLm. 
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Figure E. 18: Same as Fig. E.14, except D = 21.5 /-Lm and R - a = 0.36 fLm. 
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Figure E.19 : Same as Fig. E.14, except D = 47.8 J.lm and R- a= 0.02 J.lm. 
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F igure E. 20: Same as Fig. E.l4, except D = 35.5 J.lm and R- a= 0.00 J.lm. 
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Figure E.21: Same as Fig. E. l4, except D = 40.4 J..Lm and R- a = 0.17 J..Lm. 
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Figure E.22: Same as Fig. E. l 4, except D = 26.5 J..Lm and R- a = 0.00 J..Lm. 
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Figure E.23: Same as Fig. E .14, except D = 57.3 p,m and R- a = 0.00 p,m. 
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Figure E.24: Same as Fig. E .14, except D = 55.1 p,m and R- a = 0.02 p,m. 
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Figure E.25: Same as Fig. E.l4, except D = 36.2 f.-till and R- a = 0.35 f.-till . 
1200 5 • 
,.--., 1000 . .... . ... {/) "' !(. ...... 4 
--
•• . ·:. . ·~" . 8 800 . . .  
3 . . .. "'\. ~· ~ 3 600 . . ··"·t' 
'::::' 400 ••• ~ • 2 
200 
0 
0 5 10 15 0.002 0.004 0.006 0.008 0.010 
r (,um) R-a (,um) 
800 10 
,.--., 600 ,.--., 8 {/) ~ 
--
...... ~ '-' 400 6 '::::' 
-~ 200 ~ 4 
2 
0 
0 5 10 15 0 5 10 15 
r (,um) r Cum) 
Figure E.26: Same as Fig. E.14, except D = 33.8 J..tm and R- a = 0.00 f.-till . 
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Fig ure E .27: Same as Fig. E .l4, except D = 57.0 J..Lm and R - a = 0.00 J..Lm. 
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Fig ure E .28: Same as Fig. E.l4, except D = 24.4 J..Lm and R - a = 0.45 J..Lm . 
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Figure E .29: Same as Fig. E.14, except D = 37.5 f.Lm and R - a = 0.05 f.Lm. 
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F igure E.30: Same as Fig. E.l4, except D = 51.1 /.lm and R - a = 0.06 f.Lm. 
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E.4 N OD Mice with Chronic Hyperglycemia, Theated w ith Subsistence-
Level Insulin 
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Figure E.31: Results from a 27.9-;..tm-diameter venule in a NOD mouse chronic hyper-
glycemia, treated with subsistence-level insulin. Shown in the top left panel are raw intrav-
ital fluorescent ;..t-PIV data (gray symbols), the monotonically filtered ;..t-PIV data (black 
symbols), and the corresponding predicted axisymmetric velocity profile extracted from the 
data (curve) . The shaded region near the vessel wall represents the hydrodynamically rel-
evant endothelial glycocalyx, R - a = 0.00 ;..tm. The variation, relative to trial glycocalyx 
thicknesses, in the normalized least-squares error, E*, associated with the fit to the JJ,-PIV 
data is shown in the top right panel. T he estimated hydrodynamically effective thickness of 
the glycocalyx corresponds to the value of R- a associated with the local minimum in this 
curve. The predicted shear rate profile is shown in the bottom left panel, and the predicted 
local blood viscosity profile, relative to plasma viscosity, is shown in the bottom right. 
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Figure E.32: Same as Fig. E.31 , except D = 25.2 p,m and R- a= 0.16 p,m. 
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Figure E.33: Same as Fig. E .31, except D = 36.6 p,m and R- a = 0.29 p,m. 
177 
1200 ··~ 1000 1.8 ,-.. <Zl . . . --- 800 . . 1.6 a • • • • • • 2- 600 • • • k1 1.4 ) ';::- 400 • >:' •• •I 200 • 1.2 •: 
0 1.0 0 2 4 6 8 10 12 14 0.00 0.05 0.10 0.15 0.20 0.25 0.30 
r (,urn) R- a (,urn) 
1200 
1000 10 
,-.. 800 
,-.. 8 <Zl ~ 
---
..... 
-2: ~ 600 6 
';::- ';::-
·~ 400 '5: 4 
200 
0 2 
0 2 4 6 8 10 12 14 0 2 4 6 8 10 12 14 
r (,urn) r (,urn) 
Figure E .34: Same as Fig. E.31, except D = 29.8 f..Lm and R- a= 0.20 p,m. 
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Figure E .35: Same as Fig. E.31, except D = 41.2 f..Lm and R- a = 0.08 f.."m. 
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Figure E.36: Same as Fig. E .31, except D = 47.4 J.tm and R- a= 0.64 J.tm. 
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Figure E.37: Same as Fig. E.31, except D = 32.2 J.tm and R- a= 0.16 J.tm. 
179 
• 4.5 • 1500 . I 4 .0 ~ 
• 
"' 
---
.. • 3 .5 6 • • 
-3 1000 • ~ 3 .0 • 
--;::- 2.5 
;::;; 500 2.0 
1.5 
0 1.0 0 2 4 6 8 10 12 0.0 0.1 0 .2 03 0.4 0.5 
r (jim) R- a (jim) 
800 10 
600 8 ~ ~ 
"' $ 
---
...... 2l:: 6 '--' 400 
--;::- --;::-
·~ ~ 4 200 
2 
0 
0 2 4 6 8 10 12 0 2 4 6 8 10 12 
r (jim) r (jim) 
Figure E .38: Same as Fig. E.31 , except D = 27.2 J..Lm and R - a = 0.23 J..Lm. 
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Figure E.39: Same as Fig. E .31, except D = 46.3 J..Lm and R- a = 0.19 J..Lm. 
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Figure E.40: Same as Fig. E.31 , except D = 33.7 J..LID and R- a = 0.27 J..Lm . 
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E.5 NOD Mice with Chronic Hyperglycemia, Treated with EUK-189 in 
Combination with Subsistence-Level Insulin 
1500 3.5 
,---. 
"' 3.0 ....._ 6 1000 
_::, * 2.5 >.t.1 
-.:::- 500 2.0 ;;::-
1.5 
1.0 5 10 15 0.0 0.1 0.2 0.3 0.4 0.5 
r (Jlm) R- a (Jlm) 
1000 14 
12 
,---. 800 ,---. 
"' ~ 10 ....._ 
...... 600 ::t 
-.:::- ~ 8 -~ 400 '5:: 6 
200 4 
0 2 
0 5 10 15 0 5 10 15 
r (Jlm) r (Jlm) 
Figure E.41: Results from a 34.7-p,m-diameter venule in a NOD mouse chronic hyper-
glycemia, treated with EUK-189 in combination with subsistence-level insulin. Shown in 
the top left panel are raw intravital fluorescent p,-PIV data (gray symbols), the monoton-
ically filtered p,-PIV data (black symbols), and the corresponding predicted axisymmetric 
velocity profile extracted from the data (curve). The shaded region near the vessel wall 
represents the hydrodynamically relevant endothelial glycocalyx, R- a = 0.53 p,m. The 
variation, relative to trial glycocalyx thicknesses, in the normalized least-squares error, E*, 
associated with the fit to t he p,-PIV data is shown in the top right panel. The estimated 
hydrodynamically effective thickness of the glycocalyx corresponds to the value of R - a 
associated with the local minimum in this curve. The predicted shear rate profile is shown 
in the bottom left panel, and the predicted local blood viscosity profile, relative to plasma 
viscosity, is shown in the bottom right. 
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F igure E.4 2: Same as Fig. E.41, except D = 49.4 p,m and R- a = 0.18 p,m . 
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Figure E .43: Same as Fig. E .41, except D = 33.3 p,m and R- a = 0.00 p,m. 
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Figure E .44: Same as Fig. E .41, except D = 47.8 J..Lm and R - a= 0.74 J..Lm. 
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Figure E.45: Same as Fig. E.41, except D = 36.8 J..Lm and R - a = 0.27 J..Lm. 
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Figure E .46: Same as Fig. E.41 , except D = 31.1 f..J,m and R- a = 0.25 f.J,m. 
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Figure E .47: Same as Fig. E.41, except D = 22.8 f..J,m and R - a = 0.42 f.J,m. 
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Figure E .48: Same as Fig. E.41, except D = 40.1 J..Lm and R- a = 0.45 J..Lm . 
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Figure E.49: Same as Fig. E.41, except D = 33.5 J..Lm and R - a = 0.00 J..Lm. 
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Figure E.50: Same as Fig. E.41, except D = 49.5 J..LID and R- a = 0.30 J..LID . 
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Figure E.51: Results from a 41.1-J..Lm-diameter venule in a NOD mouse chronic hyper-
glycemia, treated with EUK-207 in combination with subsistence-level insulin. Shown in 
the top left panel are raw intravital fluorescent J..L-PIV data (gray symbols), the monoton-
ically filtered J..L-PIV data (black symbols), and the corresponding predicted axisymmetric 
velocity profile extracted from the data (curve). The shaded region near the vessel wall 
represents the hydrodynamically relevant endothelial glycocalyx, R- a = 0.67 J..Lm. The 
variation, relative to trial glycocalyx thicknesses, in the normalized least-squares error, E*, 
associated with the fit to the J..L-PIV data is shown in the top right panel. The estimated 
hydrodynamically effective thickness of the glycocalyx corresponds to the value of R - a 
associated with the local minimum in this curve. The predicted shear rate profile is shown 
in the bottom left panel, and the predicted local blood viscosity profile, relative to plasma 
viscosity, is shown in the bottom right. 
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Fig ure E.52: Same as Fig. E .51, except D = 23.1 J.Lm and R- a = 0.22 J.Lm. 
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Fig ure E.53: Same as Fig. E .51, except D = 26.3 J.Lm and R - a = 0.53 J.Lm. 
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Figure E.54: Same as Fig. E. 51, except D = 38.0 J-lm and R- a = 0.28 J-lm. 
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F igure E.55: Same as Fig. E.51, except D = 23.1 J-lm and R- a = 0.42 J-lm. 
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Figure E.56: Same as Fig. E .51, except D = 27.5 p,m and R- a = 0.40 p,m. 
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Figure E.57: Same as Fig. E .51, except D = 31.7 p,m and R- a = 0.57 p,m. 
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Figure E .58: Same as Fig. E.51, except D = 29.3 f.J-ffi and R - a = 0.29 f.J-ffi. 
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Figure E.59: Results from a 36.7-,um-diameter venule in a NOD mouse chronic hyper-
glycemia, treated with EUK-207 in combination with subsistence-level insulin. Shown in 
the top left panel are raw intravital fluorescent ,u-PIV data (gray symbols), the monoton-
ically filtered ,u-PIV data (black symbols), and the corresponding predicted axisymmetric 
velocity profile extracted from the dat a (curve). The shaded region near the vessel wall 
represents the hydrodynamically relevant endothelial glycocalyx, R - a = 0.39 ,urn. The 
variation, relative to trial glycocalyx thicknesses, in the normalized least-squares error, E* , 
associated with the fit to the ,u-PIV data is shown in the top right panel. The estimated 
hydrodynamically effective thickness of the glycocalyx corresponds to the value of R - a 
associated with the local minimum in this curve. The predicted shear rate profile is shown 
in the bottom left panel, and the predicted local blood viscosity profile, relative to plasma 
viscosity, is shown in the bottom right . 
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Figure E.60: Same as Fig. E.59, except D = 48.5 J..lm and R- a = 0.35 J..lm. 
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Figure E.61: Same as Fig. E.59 , except D = 45.4 J..liD and R- a = 0.44 J..liD. 
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Figure E.62: Same as Fig. E.59, except D = 36.6 f-ill and R - a = 0.33 J-im. 
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Figure E.63: Same as Fig. E.59, except D = 37.1 f-ill and R- a = 0.54 f-ill. 
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F igure E.64: Same as Fig. E.59, except D = 26. 1 J.Lm and R - a= 0.37 J.Lm. 
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F igure E.65: Same as Fig. E.59, except D = 32.7 J.Lm and R - a= 0.52 J.Lm. 
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Figure E.66: Same as Fig. E .59, except D = 46.6 p,m and R- a = 0.32 p,m. 
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Figure E.67: Same as Fig. E.59, except D = 33.6 p,m and R- a = 0.29 p,m. 
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